Western University

Scholarship@Western
Electronic Thesis and Dissertation Repository
4-14-2016 12:00 AM

Angiogenic Therapy in a Fibrotic Murine Model of Duchenne
Muscular Dystrophy
Kelly M. Gutpell, The University of Western Ontario
Supervisor: Dr. Lisa M. Hoffman, The University of Western Ontario
A thesis submitted in partial fulfillment of the requirements for the Doctor of Philosophy degree
in Anatomy and Cell Biology
© Kelly M. Gutpell 2016

Follow this and additional works at: https://ir.lib.uwo.ca/etd
Part of the Musculoskeletal, Neural, and Ocular Physiology Commons

Recommended Citation
Gutpell, Kelly M., "Angiogenic Therapy in a Fibrotic Murine Model of Duchenne Muscular Dystrophy"
(2016). Electronic Thesis and Dissertation Repository. 3688.
https://ir.lib.uwo.ca/etd/3688

This Dissertation/Thesis is brought to you for free and open access by Scholarship@Western. It has been accepted
for inclusion in Electronic Thesis and Dissertation Repository by an authorized administrator of
Scholarship@Western. For more information, please contact wlswadmin@uwo.ca.

Abstract
Duchenne muscular dystrophy (DMD) is a devastating neuromuscular disorder that affects
approximately 1 in 5000 males. Vascular-targeted therapy has been proposed as a
treatment for DMD to reduce ischemia and enhance endogenous repair. Additionally, a
more vascularized environment may enhance regenerative approaches currently under
investigation. Vascular endothelial growth factor (VEGF) and angiopoietin-1 (ANG1) are
two of the most studied pro-angiogenic factors for this approach. To date, little is known
regarding the effect of these pro-angiogenic factors on muscle function and whether they
may exacerbate fibrosis in a relevant murine model of DMD. The first aim of this thesis
was to determine the murine model that is best suited for assessing vascular therapy. We
demonstrate the dystrophin null, utrophin heterozygous mouse (mdx/utrn+/-) develops
more collagen deposition at an earlier age than the commonly used mdx mouse and is
therefore a superior choice for assessing therapeutic effects on fibrosis. Next, we
investigated the effect of exogenous VEGF treatment on fibroblasts derived from severely
affected diaphragm and mildly affected gastrocnemius muscles of mdx/utrn+/- mice.
VEGF treatment induced differentiation into myofibroblasts in both cell types, suggesting
induction of a fibrotic response. The final aim of the thesis was to assess the effect of
VEGF alone or in combination with ANG1 on functional perfusion as assessed noninvasively using dynamic contrast-enhanced computed tomography. A combination of
VEGF and ANG1, but not VEGF alone, slowed progression of ischemia in the mdx/utrn+/hind limb. Increased vessel maturation, as assessed histologically, validated the imaging
findings. The combination treatment also decreased fibrosis and leukocyte infiltration,
consistent with decreased vascular permeability following ANG1 treatment. Overall, the
research in this thesis highlights the drawbacks to use of VEGF as a treatment for ischemia
associated with DMD and reveals considerations for future use of vascular therapy in
murine models of the disease.

Keywords
Duchenne muscular dystrophy (DMD), fibrosis, vascular endothelial growth factor
(VEGF), angiopoietin-1 (ANG1), vascular-targeted therapy, non-invasive imaging,
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Project Proposal Summary
BACKGROUND: The most commonly diagnosed fatal childhood disorder is Duchenne
muscular dystrophy (DMD), a neuromuscular disease that is invariably fatal by the age of
30. Regenerative therapy research has been ongoing for decades with little or no
significant efficacy reported in pre-clinical trials. A major contributor to this inefficacy is
the ischemia, inflammation, and fibrosis that progressively dominate the degenerating
muscle tissue, creating a hostile environment for cell transplantation. Studies have
proposed the use of angiogenic factors to alleviate the ischemia inherent to DMD
pathology, creating a more optimal environment for regeneration. Vascular endothelial
growth factor (VEGF) is a known potent inducer of angiogenesis and is of particular
interest in the field given that preliminary. Recent studies have also proposed a
combinatorial approach, using VEGF to induce angiogenesis and angiopoietin-1 (ANG1)
to mature vessels, since VEGF alone is known to produce leaky vasculature. No studies to
date have investigated whether these factors, either alone or in combination, affect
perfusion longitudinally in a relevant animal model of DMD. There is also very little
known regarding the effect, if any, these angiogenic factors may have on inflammation and
fibrosis. Finally, much of what is currently known about vascular therapies is derived from
invasive muscle biopsies that may contribute to disease progression and are limited in that
they provide a small perspective of a very heterogeneous disease.
HYPOTHESES: A combination of VEGF and ANG1, but not VEGF alone, will reduce
disease progression in a murine model of muscular dystrophy and this effect can be
measured non-invasively using dynamic contrast-enhanced computed tomography.
SPECIFIC AIMS:
i)

Investigate histopathological features in the mdx, mdx/utrn+/- and dko mice to
determine the suitability of each as a model of Duchene muscular dystrophy.
Hallmark features that will be assessed include percentage of centrally
nucleated myofibers and extent of fibrosis as indicated by Masson’s Trichrome
staining.

vi

ii)

Determine whether VEGF elicits a pro-fibrotic response in fibroblasts derived
from a murine model of DMD. Fibroblasts isolated from gastrocnemius and
diaphragm muscles of 10 week-old mice will be treated with VEGF164. qPCR
will be employed to measure changes in mRNA levels of fibrotic genes
including Col1A, Ccn2/Ctgf, Acta2 and Fn1.

iii)

Assess the ability of VEGF alone or in combination with ANG1 to enhance the
microenvironment in dystrophic murine skeletal muscle. Ex vivo analyses
including immunohistochemistry and western blot will be used to measure
changes in expression of: alpha smooth muscle actin (marker of mature blood
vessels), CD45 (leukocyte marker), and collagen (fibrotic marker).

iv)

Use dynamic contrast-enhanced computed tomography (DCE-CT) to determine
if ex vivo changes in angiogenic, inflammatory, and fibrotic markers observed
in aim 3 correlate with functional changes in skeletal muscle perfusion.

SIGNIFICANCE: Addressing the hostile regenerative environment in dystrophic muscle
may address the lack of efficacy observed with current therapeutic approaches in DMD
patients. The proposed research will further investigate the role of vascular-targeted
therapy in vivo in a relevant animal model that more accurately reflects the
pathophysiology of DMD in patients. The majority of current research utilizes histological
and post-mortem means of assessing the effect of VEGF treatment, impeding accurate
interpretation of the effect of treatment on muscle function. The proposed research is novel
in that it will correlate CT findings with traditional histological analyses following
treatment with pro-angiogenic agents to better elucidate the potential for its use in the
clinical arena.
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A portion of this chapter includes content reproduced from:

Gutpell K, Hoffman L. Non-invasive assessment of skeletal muscle pathology and treatment for Duchenne
muscular dystrophy. OA Musculoskeletal Medicine 2013;1(4):33.
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1

Introduction

1.1 Chapter Summary
Duchenne muscular dystrophy (DMD) is the most severe form of muscular dystrophy. It
is also the most fatal genetic disorder diagnosed in children (Emery 2002). DMD is
caused by a mutation, or mutations, in the gene encoding dystrophin, a large cytoskeletal
protein that confers membrane integrity in muscle cells. Since dystrophin was discovered
in 1987, many research groups have attempted to restore its expression in patients and
animal models of the disease. Although promising results have surfaced in recent years,
100% dystrophin expression has not yet been achieved, and thus muscle degeneration and
accompanying fibrosis still occurs. As such, it is well accepted that any real cure to DMD
will involve a multifaceted approach including methods to both restore dystrophin and
alleviate the hostile muscular environment already present at the time of diagnosis.
This chapter provides background on the underlying pathophysiology of DMD,
therapeutic approaches under investigation to treat the disease, and some of the main
limitations to current research. Important considerations in conducting DMD research are
also discussed, including animal models of the disease and techniques for assessing
functional efficacy of therapies. The aim of this chapter is to provide the overarching
rationale for the research presented in this thesis.
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1.2 Duchenne muscular dystrophy
1.2.1

Living with DMD

A DMD diagnosis is typically given within the first three to five years of life. The most
common sign observed by parents is the onset of the “Gower’s maneuver,” whereby a
child cannot use his leg muscles alone to stand up. Instead, he must use his arms to
“walk” up his legs to reach a standing position. The first step in diagnosing DMD is
testing levels of creatine kinase (CK), a metabolite of muscle breakdown (Van Ruetin et
al. 2014). If CK levels are elevated, physicians will often order genetic testing on blood
samples to determine if a mutation in the dystrophin gene is present. In some, but not all
cases, a biopsy will be ordered to confirm a lack of dystrophin protein in the patient’s
skeletal muscle.
Once a diagnosis occurs, the life path that each child takes is unique, with some
responding positively to treatments and living well into their thirties, and others
succumbing to the disease by their late teenage years. Due to vast improvements in
healthcare - particularly in the fields of cardiology and pulmonology - the former case is
becoming increasingly common, with some DMD patients going to college, attaining a
career and, in some cases, having children (Eagle et al. 2002). Nevertheless, DMD
patients are limited to wheelchair mobility by approximately age 12 and the care they
receive is purely palliative, with no current treatments offering an actual cure to date
(Landfeldt et al. 2015). Eventually, patients succumb to the disease, typically due to
respiratory complications (Cruz Guzmán et al. 2012, Wei et al. 2016).

1.2.2

Murine models of DMD

The most widely studied murine model of DMD is the mdx mouse, a dystrophin-null
mouse that genotypically mimics the human form of the disease (Sicinski et al. 1989;
Partridge et al. 2013). While this model exhibits classic histological features of muscle
pathology such as centrally nucleated myofibers and inflammatory infiltrate, it is
generally healthy until 10 months of age and nearly indistinguishable from a wild-type
mouse (Stedman et al. 1991, Desguerre et al. 2012). Perhaps most importantly, the
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disease does not manifest in the same manner as it does in patients, with very little
skeletal muscle fibrosis observable at any point in the progression of the disease. The
mdx diaphragm does develop increased fibrotic marker expression, but the extent of
fibrosis is non-life threatening. Fibrosis and muscle degeneration of the diaphragm
muscle is a major cause of death in DMD patients and is therefore an important feature in
an accurate animal model. Further, fibrosis is nearly absent in the hind limb skeletal
muscles, even at an advanced age. Considering that a large portion of tissue regeneration
research in this field injects into this area, the lack of fibrosis in the mdx mouse may
present a potential source of misinterpreted results. A double knockout mouse lacking
dystrophin and its analogue, utrophin (utrn), more closely phenocopies DMD (Grady et
al. 1997). This double knockout mouse (dko) develops observable muscular dystrophy by
4 weeks of age that rapidly progresses until death, which is typically around 16-22 weeks
of age. Importantly, the dko mouse also develops fibrosis, which is a major contributor to
the severity of DMD in patients (Isaac et al. 2013). Although this double knockout model
is preferred over the mildly affected mdx mouse, it is difficult to keep this mouse alive
through the course of a longitudinal study. Additionally, in our laboratory, we observe
that disease severity ranges in this dko mouse, with some animals gaining very little
weight, only up to 10g, and barely surviving to 8 weeks of age. On the other hand, we
have a number of dko mice that grow up to 20-25g and survive with minimal intervention
up to 20 weeks of age. This disparity we observe in our dko mice introduces a great deal
of variability in our studies and makes interpretation of results difficult. Regardless, any
therapy should exhibit efficacy in the dko mouse if it holds any real promise of affecting
patients. Given these considerable issues with the mdx and dko models, the heterozygous
mouse (mdx/utrn+/-) has received attention in recent years for its potential to act as an
intermediate model, but the research findings to validate this model as superior to the
mdx mouse are still lacking.

1.2.3

DMD pathophysiology

DMD is caused by an absence of dystrophin, due to one or more mutations in the gene
that encodes the protein (Emery et al. 2002). Since the dystrophin gene is located on the
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X Chromosome, a mutation almost exclusively affects males, with female carriers of the
mutation rarely exhibiting a phenotype typical of DMD (Hoffman et al. 1987, Song et al.
2011). In very rare cases, females may carry mutations on both X Chromosomes and
therefore exhibit the full phenotype observed in male patients. The gene that encodes
dystrophin is composed of 79 exons. One or more of these exons can be mutated, with
exons 45-55 accounting for the most common sites of mutation (Blake et al. 2002).
Although DMD is an inherited genetic disorder, the mutation may also arise
spontaneously, accounting for 30-40% of DMD cases. Typically, these mutations result
in a truncated protein due to the premature addition of a stop codon. In some cases, this
truncation produces a protein that has reduced, but not completely absent, function (Laing
et al. 2011). In these cases the disease phenotype is less severe and the patient would be
diagnosed with Becker’s muscular dystrophy (Hoffman et al. 1989, Hoogerwaard et al.
1999). When the mutation results in a truncated, non-functional protein, or no protein at
all, patients are severely affected by the disease and are diagnosed with Duchenne’s
muscular dystrophy.

Dystrophin is a 427 kDa cytoplasmic protein. It is expressed in a variety of cell types,
including, but not limited to, cardiac, skeletal, and smooth muscle cells. Dystrophin acts
to link cytoskeletal actin filaments, the contractile units of myofibers, to extracellular
matrix proteins, such as laminin (Figure 1.1). Dystrophin is a component of the
dystroglycan complex, along with sarcoglycan and dystroglycan transmembrane proteins.
This link provides a scaffold against which cells may contract and confers overall
membrane integrity to myofibers (Rybakova et al. 2000). Disruption of this connection
through loss of dystrophin leads to an increased susceptibility to injury due to mechanical
stress. This lack of sarcolemma (muscle cell membrane) integrity leads to an increase in
intracellular free calcium, which has been directly linked to an increase in proteolysis,
leading to eventual cell death (Hopf et al. 1996). Rapid inflammation responds to this
muscle necrosis. The infiltrating inflammatory cells are not only responsible for clearing
away the necrotic muscle cells, but they are a major source of pro-fibrotic signalling
molecules. Of particular importance is transforming growth factor beta (TGFβ),
expressed by macrophages and other inflammatory cells, which act on resident fibroblasts
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to induce differentiation into myofibroblasts. Myofibroblasts are largely responsible for
laying down the collagen matrix that contributes to tissue rigidity and fibrosis (Desguerre
et al. 2009, Klinger et al. 2012). This cascade of events continues throughout the life of
the patient, with fibrotic and adipose tissue progressively dominating what was once
functional skeletal muscle (Figure 1.2).
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Figure 1.1: Dystrophin is an integral part of a protein complex that links the
cytoskeletal elements in muscle cells to the extracellular matrix.
As part of the dystrophin glycoprotein complex, dystrophin confers overall membrane
strength to myofibers. The N-terminal domain of dystrophin interacts with actin and the
C-terminal domain interacts with the dystrophin-associated glycoprotein (DAG)
complex, composed of sarcoglycans and dystroglycans. The DAG complex binds to
extracellular proteins in the basal lamina, such as laminin. Additionally, neuronal nitric
oxide synthase (nNOS) interacts with dystrophin between exons 42-45 at the
sarcolemma, an interaction that confers enzymatic activity to the protein.
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Figure 1.2: An X-linked mutation in the dystrophin gene leads to rapid decline in
muscle function.
A two-hit hypothesis is used to describe the pathways by which DMD progresses.
Reduced sarcolemma integrity results in an increased susceptibility to contractioninduced cellular damage. Damaged muscle tissue is continually replaced by fibrotic and
adipose tissue. At the same time, reduced nNOS activity leads to impaired vasodilation,
resulting in ischemia. Many therapeutic approaches aim to restore dystrophin in muscle
tissue.
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1.2.4

Muscle ischemia due to loss of dystrophin

Accompanying muscle degeneration is a progression of muscle ischemia in both DMD
patients and animal models of the disease (Sander et al. 2000). While the primary
function of dystrophin is to anchor the sarcolemma to the extracellular matrix for
structural stability, its presence is also important for a number of other functions in
skeletal and smooth muscle cells. Dystrophin functions as a signal transducer for the
catalytic activity of neuronal nitric oxide synthase (nNOS). Through a physical
interaction with dystrophin, nNOS catalyzes the production of nitric oxide (NO) in
skeletal muscle (van den Bergen et al. 2015, Shiao et al. 2004). NO plays a key role in a
variety of skeletal muscle cell functions including force production, regulation of blood
flow, and glucose metabolism (Sander et al. 2000). Thus, with reduced nNOS activity,
many normal functions of muscle may be impaired. Additionally, loss of dystrophin in
smooth muscle cells leads to an inability to produce vasodilation when an increased
metabolic load is placed on skeletal muscle tissue (Ito et al. 2006). As a result, there is an
unopposed sympathetic vasoconstriction leading to decreased muscle perfusion in
patients with DMD. Work by others has shown there is an increase in vasoconstriction in
DMD patients as indicated by a 16% decrease in blood flow compared to healthy forearm
muscle. Blood oxygenation is also 7% lower in DMD muscle (Sander et al. 2000).
Muscle biopsies from these patients confirm this difference in blood flow corresponds to
decreased nNOS protein levels in DMD patients. Immunohistological analysis of nNOS
shows almost no expression of the protein at the sarcolemma. The importance of
dystrophin in regulating nNOS activity is further demonstrated in transgenic mdx mice
expressing smooth muscle-specific dystrophin whereby they exhibit improved
vasoregulation compared to normal mdx mice. While vasodilation is not increased to that
of a wild type mouse in the transgenic mice, blood flow is significantly increased
compared to mdx mice lacking dystrophin in smooth muscle cells (Kobayashi et al.
2008). Overall, the deleterious effect of nNOS inactivity in DMD patients highlights a
severe need for improved vasorelaxation in DMD patients.

In addition to reduced nNOS activity in dystrophic muscle cells, there is increasing
evidence to suggest that the vascular network in dystrophic tissue is also compromised. A
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decrease in vascular density has been demonstrated in the mdx mouse (Loufrani et al.
2004 & Asai et al. 2007). Microfilm perfusion has been used to visualize the total
vasculature in the tibialis anterior muscle of the mdx mouse to demonstrate a reduced
vascular network in the mdx mouse compared to healthy controls (Matsakas et al. 2013).
Standard immunohistochemical techniques also indicate reduced arteriole density in mdx
mice. It has not been reported whether a decrease in vascular density exists in DMD
patients, but it is well known that fibrotic and fatty deposits progressively dominate
muscle tissue in DMD patients. The dense, fibrotic connective tissue that displaces
muscle is not well vascularized and therefore may impede blood delivery to the tissue.
Without proper blood flow, muscle regeneration, by endogenous repair mechanisms or
exogenous dystrophin delivery, may not occur. Enhancing the vascular environment by
increased vascular density may confer some of the function that is aberrant due to a lack
of dystrophin.

Dystrophin absence in endothelial cells (ECs) has also been linked to impaired
angiogenesis in mdx mice (Palladino et al. 2013). Although dystrophin was classically
considered to be a muscle-specific protein, this study demonstrates the importance of its
expression in ECs as well. As with muscle cells, the loss of nNOS activity at the EC
membrane leads to a cGMP deficiency that affects not only blood blow, as previously
discussed, but also impairs the ability of ECs to migrate, proliferate, and form tubules in
in vitro culture assays. Interestingly, a low dose of aspirin aided in EC production of NO
and cGMP, leading to an increase in microvascular density post-treatment. These
findings shed a new light on the use of pro-angiogenic growth factors for enhancing the
microvasculature in mdx mice and DMD patients. Prior to this study, little attention has
been given to the possibility that, regardless of growth factor treatment, there may be an
inherent impairment in EC ability to form new vessels in muscular dystrophy. Thus, the
results of this study may help explain differences in angiogenesis following treatment in
dystrophic compared to healthy muscle.

There is evidence of decreased vasodilation, vascular density, and angiogenic capability
in dystrophin-related myopathy. Taken together, studies relating to ischemia in DMD
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highlight the need to not only address ways to regenerate muscle cells, but also address
the vascular problems inherent in this pathology. Without proper vasculature,
regenerative techniques to restore dystrophin may be rendered futile.

1.3 Strategies to restore dystrophin
Given the importance of dystrophin in nNOS activity and conferring sarcolemma
integrity, a number of groups are attempting to restore dystrophin expression in animal
models of DMD. Some of the most promising approaches to restoring dystrophin include
exon skipping, genome editing using the Crispr/Cas9 system, and stem cell therapy.

1.3.1

Exon skipping

When a genetic mutation disrupts the reading frame of nucleotide triplets, or codons, the
result may be a truncated protein. This is the case in DMD whereby a mutation in one or
more exons leads to a premature stop codon, resulting in a truncated, non-functional form
of the dystrophin protein. In most cases, this truncated version of the protein is not even
detectable as dystrophin. Fortunately, cells have an inherent ability to excise, or “splice”,
introns, which are portions of a pre-mRNA strand that do not contribute to the amino acid
sequence of a peptide. Researchers have exploited this innate machinery in cells to splice
out the mutated exons in the dystrophin gene (Hoffman et al. 2014). The result is an
imperfect, but largely functional, dystrophin protein. Eteplirsen, developed by Sarepta
Therapeutics, has been used in Phase III clinical trials to treat patients with a mutation in
exon 51, one of the more commonly mutated sites in DMD. The United States Food and
Drug Administration is reviewing Sarepta’s New Drug Application for Eteplirsen in
February 2016. Although only 13% of DMD patients may be amenable to exon 51
skipping, this technology could significantly improve quality of life for that patient
population (Mendell et al. 2016). It is important to note, though, the dystrophin expressed
in these cases often lacks its full function and only improves the disease phenotype to a
less severe form, one similar to that observed in Becker’s muscular dystrophy.
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1.3.2

Genome editing

In contrast to exon skipping, whereby the mutation is left intact and a downstream target
(RNA) is manipulated, genome editing involves correcting the mutation that is embedded
in the genetic code. A powerful new genome editing tool known as clustered regularly
interspaced short palindromic repeat/Cas9 (CRISPR/Cas9) has emerged as one of the
most promising tools of the 21st century. This system involves the use of RNA to guide a
nuclease (Cas9) to a specified site in the genome to induce a double-stranded break. An
exogenous template is then used to modify the mutated site, thereby correcting the
original defect in the gene. Various groups have used CRISPR/Cas9 to introduce
dystrophin expression in vitro to immortalized DMD-derived myoblasts and in vivo to the
mdx mouse, the most commonly used model of DMD (Iyombe-Engembe et al., 2016,
Long et al. 2014, 2016, Nelson et al., 2016 Tabebordbar et al., 2016). An important
aspect of the CRISPR system that renders it perhaps more useful than current exon
skipping practices is the ability to excise a large fragment of DNA, spanning a number of
exons. By covering the mutations in exons 45-55, CRISPR/Cas9 offers the potential to
address over 60% of DMD cases.

1.3.3

Cell therapy

The chief self-renewing muscle progenitor cell is the satellite cell (SC), named for its
location under the basal lamina. SCs are the primary physiologically relevant stem cell
population contributing significantly to muscle regeneration (Murphy et al., 2011, Chang
et al. 2014). When satellite cells are activated, they undergo myogenesis, differentiating
into myoblasts that fuse with each other to form multinucleated myotubes (Figure 1.3).
Given the ability of SCs and other muscle progenitor cells to undergo myogenesis,
various groups are looking at these populations as ways to introduce dystrophinexpressing stem cells into dystrophic muscle (Mendell et al. 1995, Skuk et al. 2006,
2007). Stem cell therapy has been one of the most widely studied- and perhaps most hotly
contested- approaches to treating DMD. Clinical trials involving muscle-specific stem
cells have been ongoing since the 1990’s. There is evidence of donor cells present in
recipient tissue up to 13 years post implant, suggesting the possibility for using cell
therapy in the future (Gussoni et al. 2002, Skuk & Tremblay 2016). Although these initial
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studies have furthered our knowledge regarding the role of various cell populations in
regenerating lost muscle, there have been no widespread reports of any cell therapy
having significant effects on muscle function following treatment. There are a number of
ongoing clinical trials with estimated completion dates in 2016-2018 using various
populations of stem cells including umbilical cord-derived mesenchymal stem cells and
bone marrow-derived stem cells. Rita Perlingeiro’s group is currently investigating the
efficiency of induced pluripotent stem cells to regenerate muscle in mdx mice (Filareto et
al. 2012). This approach involves isolating skin fibroblasts from mdx mice/DMD patients,
reprogramming them back to a pluripotent stem cell state, correcting the dystrophin
mutation, and implanting them back into the host. This approach is attractive in that it
uses an autologous transplant, which largely mitigates the chances of stem cell rejection
post-implant.

While cell therapy research may be promising for the future, this and other regenerative
approaches face a significant hurdle in that they attempt to introduce dystrophin into a
hostile, fibrotic environment that is not conducive to regeneration (Klinger et al. 2012).
The “seed and soil” hypothesis, often referred to in cancer research, is also applicable to
regenerative therapy for DMD. Regardless of the regenerative capacity of any specific
cell population, its potential for reconstituting muscle is dependent on the transplantation
environment. Given the inflammation and fibrosis that is so prominent in muscular
dystrophy, it is not surprising that cells do not survive after transplantation. Since parents
are often unaware their child is affected until 1-6 years of age, this pathogenesis has
already been initiated and any therapeutic approaches would involve the presence of
inflammation and potentially fibrosis. Thus, in addition to researching methods for
introducing dystrophin into muscle, there is also a need to find ways to improve the
hostile environment that will receive cell transplantation.
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Figure 1.3: Muscle-specific stem cells known as satellite cells undergo myogenesis to
form muscle tissue.
Satellite cells, while present in DMD patients, are quickly exhausted and the process of
myogenesis is insufficient to meet the demands of reconstituting muscle in patients.
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Figure 1.4: VEGF and ANG1 play a role in angiogenesis by eliciting different
responses upon binding to their receptors on endothelial cells.
Upon binding to its type-2 receptor (VEGFR-2), VEGF increases endothelial pores
through p38/MAPK signaling, allowing for extravasation of leukocytes from the blood
into tissue. Upon activation of phospholipase C-gamma (PLC-ϒ), signaling through the
Raf/MEK/MAPK pathway results in DNA synthesis and cell proliferation. Upon ANG1
binding to the Tie2 receptor, vascular-endothelial (VE) cadherin increases cell-cell
interaction for increased barrier function. ANG1 also increases vascular smooth muscle
cell (SMC) recruitment indirectly by increasing expression of endothelial cell (EC)derived chemoattractants, such as platelet-derived growth factor, hepatocyte growth
factor, and heparin-binding epidermal growth factor. Binding of both VEGF and ANG1
to VEGFR-2 and Tie2, respectively, lead to increased cell survival through
phosphoinositide 3-kinase (PI3K) activation. Portions of the figure adapted from
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Ilvanainen et al. 2003; Kobayashi et al. 2006, Shibaya & Claesson-Welsh 2006, Olsson et
al. 2006; Li et al. 2015).

1.4 Vascular targeted therapy for DMD
Vascular therapy has been identified as a potential treatment for DMD (Ennen et al.
2013). Since vascular endothelial growth factor (VEGF) has long been accepted as a
master regulator of vessel development, groups are attempting to increase its functionthrough receptor modulation or administration of the growth factor itself- to enhance the
vasculature in animal models of DMD. VEGF exerts its effect by binding to its type II
receptor, VEGFR2, inducing receptor dimerization, leading to phosphorylation of
intracellular tyrosine residues (Ruch et al. 2007). Activation of VEGFR2 can lead to
increased signalling through a variety of pathways, but the most relevant to the
angiogenic response in endothelial cells is the RAS/RAF/MEK/MAPK pathway,
although the details have not been fully elucidated (Meadows et al. 2001). Ras activation
in ECs has been shown to play a role in proliferation, migration, and branching cues.
Importantly, VEGF binding to VEGFR2 also increases vascular permeability through
formation of endothelial pores (Garrido-Urbani et al. 2008). Although VEGF induces an
angiogenic response, the newly formed vessels are “leaky”, lacking functional maturity,
which may impede any enhancements to the blood flow. As such, it is hypothesized that
use of VEGF in combination with other factors may be necessary to attain fully
functional vessels. One factor in particular is the secreted glycoprotein angiopoietin-1
(ANG1), a member of the angiopoietin family of growth factors. By binding to the Tie2
receptor, ANG1 plays a vital role in endothelial remodelling (Baffert et al. 2004 &
Thurston et al. 2005), vascular reinforcement (Gamble et al. 2000), and vessel survival
(Cho et al. 2004). ANG1 is therefore under investigation for a range of diseases including
sepsis and stroke (Sato et al. 2005). Given its role in promoting vascular maturity during
both development and in adult tissue, ANG1 is a prime candidate to exert synergistic
effects along with VEGF in dystrophic, ischemic muscle.
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Another reason angiogenic growth factor supplementation may be beneficial to DMD
patients is the fact that current gold standard medications may interfere with endogenous
VEGF action. Glucocorticoids (Prednisone, Deflazacort), are the cornerstone therapy
currently offered to DMD patients, with therapy beginning around five years of age.
Randomized controlled trials that originated in the late 1980’s revealed a short-term
benefit to patients receiving glucocorticoids, evidenced by improved muscle function for
six months to two years, but long term benefits were not apparent (Mendell et al. 1989).
Although this study occurred decades ago, glucocorticoid treatment is still prescribed
based on these findings. One potential explanation for this lack of long-term efficacy may
reside in the fact that glucocorticoids inhibit VEGF and MMP-2 (Ishiguro et al. 2014).
Matrix metalloproteinase-2 (MMP-2) is a promising candidate for enhancing VEGFinduced angiogenesis since it increases the ability of endothelial cells to degrade ECM
components and invade through the matrix. Thus, while glucocorticoids may reduce
inflammation, they may also be acting to reduce angiogenesis and perhaps contribute to
the long-term progression of disease. It is possible that increasing circulating VEGF
levels through treatment may alleviate this undesired effect of glucocorticoids and
increase their efficacy as well.

1.4.1

Vascular therapy to reduce muscle ischemia

Proper blood delivery is vital to maintenance of healthy organs. In a highly metabolic
tissue such as skeletal muscle, proper blood flow is crucial for delivering oxygen and
nutrients that are in high demand, particularly during exercise and contractions required
from day-to-day movements. The vascular response is crucial in mediating changes in
blood flow, inducing vasodilation when there is an increased metabolic demand. Thus, in
DMD patients in whom vasodilation is impaired, oxygen and nutrient delivery is reduced
(Nelson et al. 2014). Although muscle ischemia is not the primary culprit responsible for
the DMD pathology, it certainly perpetrates myonecrosis, adding to overall disease
progression. Specifically, functional ischemia plays an integral, although not exclusive,
role in contraction-induced muscle damage (Asai 2007). Increasing vasodilation via
phosphodiesterase-5 (PDE-5) inhibitor, tadalafil, has been shown to lessen the extent of
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myofiber damage in the mdx mouse (Adamo et al. 2010 Percival et al. 2012). In DMD
patients, sildenafil, another PDE-5 inhibitor, rescues exercise-induced hyperaemia
(Nelson et al. 2014). These findings highlight the value of increasing blood flow in the
poorly perfused dystrophic skeletal muscle. An important question that is still
unanswered is whether restoring blood flow actually slows disease progression in
dystrophic muscle.

1.4.2

Vascular therapy to enhance endogenous repair

One of the main goals of vascular therapy is to introduce a factor, or factors, that act on
vascular cells (endothelial cells, smooth muscle cells), to increase their function in the
vascular network. An added benefit of vascular therapy that has been elucidated since the
early 2000’s is its effect on endogenous repair mechanisms. A number of studies have
eloquently demonstrated that endogenous repair mechanisms are insufficient in DMD and
animal models of the disease (Sacco et al. 2010, Dumont et al. 2015). In healthy
individuals, muscle-specific stem cells, known as satellite cells, are largely responsible
for this repair mechanism by regenerating new myofibers. A 2010 study by Sacco et al.
demonstrated a reduced regenerative capacity of SCs derived from dystrophic muscle.
Due to shortened telomere length and decreased telomerase activity, SCs in dystrophic
skeletal muscle are unable to keep up with the self-renewal required to regenerate lost
tissue. A 2015 study by Dumont et al. has received a great deal of attention for
uncovering another deficient mechanism in mdx SCs. For decades, researchers have
shown that myoblasts in culture do not express dystrophin, but this study showed, for the
first time, that SCs do express the protein and that it is necessary for proper cell polarity.
This polarity gives SCs important cues regarding needs for replication, activation, and
differentiation. Thus dystrophin-deficient SCs do not receive proper environmental cues
and therefore lack their full function. This study has paved the way for DMD to now be
classified not only as a muscle-wasting disease, but also as a stem cell disease. Taken
together, these studies have highlighted the need to improve endogenous repair
mechanisms in a system where this process is quickly exhausted.
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Viral delivery of VEGF has demonstrated its ability to improve endogenous repair in
skeletal muscle. Following injection of recombinant adeno-associated VEGF (rAA
VEGF), histological findings show an increase in myogenin-positive SCs. Myogenin is
expressed early in myogenesis and is therefore a good indicator of regeneration. This
study also demonstrated a significant increase in the number of regenerating myofibers
compared to mdx mice receiving a control injection (Messina et al. 2007). Similar results
were observed in a hind limb ischemia model and the glycerol and cardiotoxin models of
muscle injury (Arsic et al. 2004). It is now well accepted that SCs express both VEGF as
well as its receptor, VEGFR-2, and in fact, in healthy skeletal muscle, SCs account for
the majority of VEGF and VEGFR-2 expression.

1.4.3

Vascular therapy to enhance cell therapy

In regards to using vascular therapy as an adjunct to other therapeutic approaches, there is
a growing body of evidence to suggest that it may enhance the engraftment and function
of transplanted cells. A major hurdle of current cell therapy approaches is the lack of
survival, migration, proliferation, and function of transplanted cells. In 1977,
Schmalbruch et al. discovered that SCs reside in close proximity to microvasculature,
suggesting a possible role for blood vessels in directing the movement of stem cells.
Indeed, a 1984 study by Venkatasubramanian and Solursh demonstrated that embryonic
skeletal muscle cells migrate toward a gradient of growth factors whereas other
mesenchymal cell types present in the limb bud do not exhibit this chemotactic
behaviour. The finding that myoblasts migrate towards areas of existing vasculature, due
to secretion of pro-angiogenic growth factors, has prompted researchers to investigate the
ability of angiogenesis to aid in the migration of transplanted myoblasts. Thus, in 2001,
Corti et al. tested the ability of various growth factors to enhance migration of C2C12
myoblasts across an endothelial layer. Various growth factors, in particular hepatocyte
growth factor as well as platelet-derived growth factors A and B significantly increased
migration of myoblasts. VEGF has also been shown to increase migration of C2C12
myoblasts and SCs in the Boyden chamber assay, an in vitro experiment used to measure
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cell migration (Germani et al. 2003). The hypothesis that VEGF may in fact enhance cell
transplants was put to the test in a study assessing the effects of the growth factor on
muscle derived stem cell transplants into the mdx mouse (Deasy et al. 2009). VEGF was
shown to increase proliferation and differentiation of the stem cells in vitro, lending
further evidence that VEGF does not act solely on endothelial cells in the context of
DMD treatment. Although this group reported an increase in endogenous repair, decrease
in fibrosis, and increase in microvasculature following transplantation of VEGFexpressing muscle stem cells, VEGF expression did not result in an increase in
dystrophin-positive myofibers, which would be expected if these cells had indeed
contributed to the new muscle. The authors do postulate, however, the lack of dystrophinpositive fibers could be due to the pro-proliferative effect of VEGF on MDSCs, resulting
in increased proliferation of these transplanted cells, but not necessarily increased
differentiation. Interestingly, a more recent study from the same group demonstrated the
regenerative capacity of MDSCs is reduced when VEGF signalling is inhibited (Beckman
et al. 2013). This study and others have highlighted the beneficial effect of VEGF on cell
transplants, but have proposed that it may be through mechanisms other than enhancing
the engraftment of these cell populations contribute to the reconstitution of the muscle
(Distefano et al. 2013). VEGF as a proliferative stimulus may increase the survival of
transplanted cells, thereby allowing them to exert a paracrine effect for a larger amount of
time, contributing to further endogenous repair in the muscle. Overall, based on the
chemotactic effect of pro-angiogenic factors such as VEGF, future studies using
angiogenesis as a pre-treatment for cell transplants may augment the effect of these cells
following treatment.

1.4.4

Limitations to current vascular therapy

Given the potential of angiogenesis to enhance both endogenous repair and cell therapy
for treating DMD, methods for increasing VEGF, a potent inducer of angiogenesis, are
attractive. Although an impressive body of research supports the potential efficacy of
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VEGF as a DMD drug, the majority of studies have used viral methods to deliver the
growth factor. Although adeno-associated viruses have been used in a number of clinical
trials and appear to be relatively safe, it is not yet clear whether the actual dose of VEGF
expressed in the tissue could be predicted in a consistent manner. This concern is of
special importance considering the findings that describe formation of hemangiomas
following long-term exposure to VEGF treatment at high doses (Springer et al. 1998, Lee
et al. 2000). Thus, it would be of particular value to deliver the growth factor at a low
dose in a more controlled manner.

The standard method for determining the effect of vascular therapy on angiogenesis is ex
vivo histology. Elevation in expression of CD31, a marker of endothelial cells, is the most
commonly used measurement of angiogenesis. Since CD31 is also a marker of
macrophages and neutrophils, extreme care must be taken to ensure that measurement of
this marker excludes any type of inflammatory cells present in dystrophic muscle.
Further, CD31 marks the endothelial layer, but it does not mark functionally mature
vessels. Thus, in addition to CD31, assessing alpha-smooth muscle actin expression in
vascular smooth muscle cells may demarcate vessels that confer functional benefit to the
muscle. Much like CD31 staining, though, extreme care must be taken to ensure
distinction is made between αSMA that marks blood vessels compared to that which
marks myofibroblasts. Previous studies that have reported changes in either CD31 or
αSMA do not elaborate on the methods used to quantify expression of these markers
histologically. Even taking these limitations into account, very few studies go beyond
histological findings to assess the functional efficacy of vascular-targeted therapy. Thus,
there is little evidence, to date, that VEGF, with or without ANG1, actually affects
functional perfusion. Therefore, it is absolutely critical to determine whether or not these
factors may affect perfusion and correlate those findings to conventional histological
data.

Transplant studies using cells expressing VEGF have demonstrated a decrease in fibrosis
following treatment. While these findings may suggest an anti-fibrotic role of VEGF in
dystrophic muscle, this is an important assumption that has not yet been rigorously tested.
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The importance of fibrosis in DMD has gained more attention in recent years and any
therapeutic approach under investigation should specifically assess its effect on fibrosis
in this disease. To do so, an appropriate animal model, one that develops significant
fibrosis, must be used. There is currently a lack of data to support the anti-fibrotic role of
VEGF in DMD. Given that VEGF has been shown to exacerbate extracellular matrix
(ECM) deposition in other fibrotic diseases such as scleroderma and idiopathic
pulmonary fibrosis (Maurer et al. 2014 & Hostettler et al. 2014), it is plausible that VEGF
may also exert a pro-fibrotic response in DMD. Testing the effect of VEGF at an
appropriate stage of disease progression and in a relevant model should be done prior to
moving to larger animal models and, certainly, prior to clinical studies.

1.5 Functional assessment of therapeutic efficacy
While vascular-targeted therapy offers significant potential for the treatment of DMD,
current research is hindered by an important limitation. The standard method for
assessing the effect of vascular therapy is through invasive muscle biopsies that may
themselves contribute to further disease progression (Forbes et al. 2013; Triplett et al.
2014). In addition to the invasive nature of muscle biopsies, information gleaned from
this tissue is limited to histological (H&E, Masson’s Trichrome stains), biochemical, and
molecular (western blotting, gene expression) analyses that preclude any sort of
longitudinal, functional assessment. DMD manifests as a very heterogeneous disease
affecting certain muscle groups differently (Forbes et al. 2013; Triplett et al. 2013). In
fact, some muscle groups appear nearly unaffected in DMD. Depending on the tissue
region selected for biopsy, this sample may drastically over or underestimate the true
extent of therapeutic efficacy in the patient. Thus, there is a critical need for ways to
noninvasively assess disease progression and subsequent efficacy of therapeutic
interventions.

1.5.1

Laser Doppler Imaging

Laser Doppler imaging (LDI) utilizes infrared light to monitor the movement of blood
cells in the microvasculature. Since it is an optical technique, it is primarily used to
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monitor blood flow in superficial tissues, such as in skin, to assess burns and the extent of
fibrosis in systemic scleroderma, as well as intraoperatively during brain surgery.
Researchers have used it to assess blood flow in a rodent hind limb ischemia model in
rodents. In this model, an incision is made in one hind limb and the femoral artery is
occluded, inducing ischemia in that limb. LDI is then used to monitor re-perfusion of that
muscle over time. In recent years, groups have used the hind limb ischemia model to
assess angiogenic capabilities in mdx mice (Palladino et al. 2013) and the effect of cell
therapy on blood flow (Brenes et al. 2012). While these studies have tremendous value in
demonstrating functional changes in the disease with and without a therapeutic
intervention, there are inherent limitations to the use of LDI to assess therapy in DMD
research. Depth of penetration is minimal, with the average depth capable of imaging via
laser Doppler being 1mm (Rajan et al. 2008), although this value is strongly dependent
on wavelength. This limited penetration makes LDI suitable for skin and superficial
imaging, but not suitable for deeper tissues without invasive surgery. The degree of
ligation is also a source of variability in inducing ischemia, opening up a potential source
of misinterpreted results. Lastly, and perhaps most importantly, the hind limb ischemia
model is an acute, invasive technique, suitable for animal research only. Although LDI
studies provide valuable insights into functional effects of therapeutic intervention, a
number of modifications would be required to use LDI to assess vascular therapy in
patients. It would be invaluable to use a functional imaging tool that could be performed
in both preclinical animal models as well as patients to better elucidate what differences
may exist in treatment responses. Further, in a disease characterized by inflammation and
constant muscle degeneration, studying therapeutic efficacy following an additional
surgical injury may introduce a source of confounding results.

1.5.2

Non-invasive imaging

While the use of LDI in the hind limb ischemia model offers a number of advantages for
basic researchers, it is not a practicable option for patient studies. The potential benefits
that non-invasive imaging offers for both monitoring disease status and therapeutic
outcome are numerous and may change our understanding of DMD progression and
treatment. From the perspective of a patient, non-invasive imaging would eliminate the
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need for painful muscle biopsies, which are the typical method of assessing muscle
damage. The biopsy process itself may also induce further damage to already injured
muscle. From the perspective of a researcher, non-invasive imaging allows for a more
global analysis of what is happening in vivo, an advantage not offered by ex
vivo histological analyses. It has also been suggested that changes observed noninvasively may precede changes in physiological outcome, i.e. muscle contractile
strength and endurance (Ahmad et al. 2010), which is important when considering the
timing of therapeutic intervention. It should be noted, however, that non-invasive
imaging is not yet able to definitively diagnose DMD in patients (Grounds et al. 2008
Kuru et al. 2013). While new blood tests for detecting specific mutations in the
dystrophin gene are being developed (Kim et al. 2010), it would be advantageous to
investigate the use of non-invasive imaging for diagnostic purposes as well. Regardless,
computed tomography (CT), magnetic resonance imaging (MRI), and positron emission
tomography (PET) may be viable options to non-invasively assess disease progression
and therapeutic efficacy.

1.5.2.1

DCE-CT

X-ray computed tomography (CT) technology utilizes computed-processed X-rays to
produce a three-dimensional image of the internal structures of an object. Dense tissues
such as bones will attenuate an X-ray more than tissues that are composed largely of
water or air. CT resolutions between tissue densities allow researchers to distinguish
between tissues that vary by only 1% in their densities, making it an ideal tool to image
fat and muscle tissue (Gellerich et al. 1990; Goodpaster et al. 2000).

Given these

characteristics, CT has been in use since the 1980’s to monitor structural changes in
dystrophic skeletal muscle, becoming a gold standard in assessing muscle degeneration.
While dynamic contrast enhanced CT (DCE-CT) has not been widely used in the DMD
research field, it has made significant contributions to the diagnosis and treatment
strategies of other diseases. DCE-CT has significantly improved outcomes for stroke
patients by helping to distinguish stroke sub-types, which has enhanced patient quality of
life and lessened the economic burden associated with poorly managed stroke treatment.
There are some important limitations to using CT to assess muscle involvement in DMD

25

patients, which may explain the lack of routine clinical use. First, there are concerns with
x-ray exposure to humans; repeated scans during a longitudinal study may be particularly
unsafe for pediatric patients (Brenner et al. 2001). Current research is attempting to
implement dose reduction methods using various software and hardware techniques that
may reduce radiation dose by 2–3 fold, making it more suitable for use in young patients
(Lee et al. 2010). Additionally, most CT methods are unable to distinguish between
connective tissue and muscle, which makes it difficult to assess extent of fibrosis, another
hallmark of DMD (Liu et al. 1993; Nakayama et al. 2013). Dynamic contrast-enhanced
CT (DCE-CT) may address this issue by providing measurements of perfusion in skeletal
muscle. Since fibrotic tissue is largely under perfused, blood flow to those areas is limited
and thus may be detected via DCE-CT. The use of a radiopaque contrast agent, such as
iodine with a high atomic number, is also ideally suited to monitor changes in muscle
ischemia that are inherent to disease progression in DMD. DCE-CT has been used to
assess changes in blood flow in the mdx mouse following exercise and to monitor disease
progression in a severely affected model of DMD (Ahmed et al. 2011). While these
results point to the usability of DCE-CT in murine models of DMD, no study to date has
used this tool to assess therapeutic intervention.

1.5.2.2

MRI and PET

Magnetic resonance imaging (MRI) is an ideal imaging modality for visualizing the
anatomy of soft tissue within the body, thus offering many potential benefits for use in
assessing muscle pathogenesis in both animal models of DMD, DMD patients and other
patients suffering from a broad spectrum of myopathies (Lamminen et al. 1990, a,b; Liu
et al. 1993). Magnetic resonance imaging (MRI) involves placing a subject in a strong
magnetic field, which results in the alignment of hydrogen nuclei that are part of water
molecules. When an external radio wave is applied to the subject in the magnetic field,
some of the nuclei are excited. After relaxing from this excited state, the released energy
produces small radio signals, or pulses, that are detected by the scanner, in both time and
space. The time it takes for the longitudinal or transverse excitations to relax are referred
to as T1- and T2-relaxation times, respectively. Imaging techniques focused on transverse
relaxation times produce images with areas of high water content appearing dark (weak
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signal strength), and areas of higher fat content appearing bright (strong signal strength).
To this end, MRI has been utilized to distinguish healthy versus dystrophic muscle in the
mdx mouse (McIntosh et al. 1998). Specifically, T2-weighted images illustrate that
degenerating muscle in mdx mouse hind limbs appear more heterogeneous on an MR
image compared to hind limb musculature of a wild-type mouse, which appears largely
homogeneous; higher T2 values were attained in control muscles and these regions of
interest appeared “lighter” than in the degenerating muscle in mdx mice. Histologically,
the “dark” areas on a T2 map were found to correspond to areas of inflammation and
macrophage infiltration in dystrophic muscle lesions, as validated histologically.
Additionally, some areas on a T2 map of dystrophic hind limbs exhibited an intense
signal, indicating the presence of fatty infiltrate in the mdx mouse that was not present in
healthy wild-type hind limb musculature (Dunn et al. 1999). Recent work by
Vandenbourne and colleagues, confirms the use of T2 mapping to assess changes in
skeletal muscle of the lower extremities in DMD patients aged 5–15. Specifically, this
group confirmed that T2 values are elevated in lower limb muscles of DMD patients
versus healthy, age-matched control subjects, including younger subjects between the
ages of 5 and 8. Interestingly, these differences in T2 values correlated well with
functional tests of muscle contractile strength tests in these individuals. Another recent
study from 2010 reported the use of T2 mapping to examine the effect of corticosteroid
treatment—the current gold standard therapy to inhibit/reduce inflammation—in DMD
patients relative to both untreated and healthy patients. While patient compliance is
always a potential issue given the age of DMD patients, MRI may be safely repeated and
confers no pain to the individual. Furthermore, MRI does not involve ionizing radiation,
making it an attractive tool for pediatric patient use. Taken together, these studies provide
compelling evidence that MRI may be a valuable tool for providing information on
global changes in muscle composition as disease progresses, with or without the use of
therapeutic interventions.
While MRI and CT are useful for their detailed anatomical data and high resolution, PET
imaging may offer more information in regards to muscle function in animal models and
in DMD patients. PET involves the use of a radiolabeled substance that will emit
positrons after injection into the body. When a positron collides with a nearby electron,
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two 511 keV photon are created. Detectors in the PET scanner capture this coincidence
event allowing for localization of the collision. Thus, depending on the radiolabeled
substance, various types of cells and tissues can be imaged. The most widely used
substance in patients today, mainly as a standard diagnostic imaging tool for cancer is
fluorine[18]-labeled fluorodeoxyglucose (18F-FDG), a glucose analog. Cells that express
the GLUT-1 glucose transporter, mainly metabolically active cells, take up

18

F-FDG.

While some studies have used FDG-PET for assessing muscular dystrophy-related
cardiomyopathy in patients (Quinlivan et al. 1996), it has yet to be assessed in significant
studies of skeletal muscle metabolism in DMD patients. There is strong evidence that
FDG-PET will be a useful tool for monitoring inflammation in myopathies as indicated
by a progressive increase in FDG uptake compared to wild-type controls (Tateyama et al.
2015, Al Nahhas et al. 2011).

While PET imaging may be a promising avenue for longitudinally assessing muscle
degeneration and therapeutic interventions, there are a few limitations that must also be
considered. First, more work needs to be conducted to determine the utility of FDG as a
radiolabel for inflammatory cells. Although inflammatory cells express the GLUT-1
receptor, muscle cells, which are highly metabolic, express this receptor as well. As such,
changes in FDG uptake could be due to changes in inflammation or due to changes in
muscle metabolism. Thus, more proof-of-principle studies will be required prior to using
FDG in the context of DMD. Similarly, although MRI offers considerable advantages for
imaging skeletal muscle, there are still drawbacks to using this modality. Hence CT is
most optimal for preclinical studies in DMD research. Imaging time is significantly
longer for MRI compared to CT, which is a drawback for both pediatric patients as well
as preclinical studies in mice whereby a mouse would need to be anesthetised for hours
compared to just minutes for CT. In terms of feasibility, the cost of an MRI scan is much
higher than for a CT scan and, for clinical studies, claustrophobia and patient compliance
would be a more significant issue using MRI.
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1.6 Thesis hypotheses and specific objectives

1.6.1

Hypotheses

A combination of VEGF and ANG1, but not VEGF alone, will enhance skeletal muscle
perfusion in a murine model of muscular dystrophy and this effect can be measured noninvasively using dynamic contrast-enhanced computed tomography.

1.6.2

Specific objectives

Chapter 2
i)

Investigate histopathological features in the mdx, mdx/utrn+/- and dko mice
and compare those findings to C57BL/10 mice to determine the suitability of
each as a model of Duchene muscular dystrophy.

Chapter 3
ii)

Determine whether VEGF elicits a pro-fibrotic response in fibroblasts derived
from a murine model of DMD.

Chapter 4
iii)

Assess the effect of VEGF alone or in combination with ANG1 on the
microenvironment (i.e. vasculature, collagen deposition, and inflammatory
infiltration) in dystrophic murine skeletal muscle.

iv)

Employ dynamic contrast-enhanced computed tomography (DCE-CT) to
determine if ex vivo changes in angiogenic, inflammatory, and fibrotic
markers observed in aim 3 correlate with functional changes in skeletal
muscle perfusion.
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Skeletal Muscle Fibrosis in the mdx/utrn+/- Mouse Validates Its
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2

Skeletal muscle fibrosis in the mdx/utrn+/- mouse
validates its suitability as a murine model of DMD

2.1 Chapter Summary
The mdx mouse and X-linked canine muscular dystrophy are the two most widely used
animal models of DMD. Given the ethical concerns regarding the use of canine models
for basic research, the mdx mouse is by far the most commonly cited model in preclinical
studies. Although the dystrophin-null mdx mouse genotypically mimics the human
disease, recent focus on the importance of fibrosis in DMD highlights the importance of
this aspect be represented in any suitable model. Since our research focus on the use of
angiogenic factors as a treatment for DMD and other studies have suggested the ability of
some angiogenic growth factors to induce fibrosis, using a model that is more prone to
fibrosis is absolutely critical in the accurate assessment of therapeutic side effects. The
presence of utrophin, a dystrophin analogue, inversely correlates with disease
progression. Therefore, the mdx (utrophin +/+), heterozygous (mdx/utrn+/), and double
knockout (mdx/utrn-/-) mice all represent varying degrees of disease severity. In the
present study, we compare disease pathology in the mdx mouse with the other two
models. Importantly, we also compare disease pathology to the C57BL/6 wild type
mouse to provide an accurate margin for classifying fibrotic from non-fibrotic muscle
tissue. Using extent of collagen deposition and number of centrally nucleated myofibers
as indicators of disease severity, we show that the heterozygous mdx/utrn+/- mouse is a
superior model to the mdx mouse since extent of collagen deposition is greater by 7-8
weeks of age compared to the wild-type or mdx models. This study established the best
model and age to incorporate in the subsequent studies described in this thesis.
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2.2 Introduction
Treatment strategies for Duchenne muscular dystrophy (DMD), a severe neuromuscular
degenerative disorder, have been ongoing for decades with little significant long-term
efficacy reported (Pichavant et al. 2011). While scientific and technological
advancements have enhanced patient quality of life, the disease remains invariably fatal.
The majority of current research into treating DMD involves the restoration of the protein
dystrophin, which is absent or non-functional in these patients. Of these, a number of
studies in DMD patients have used cell therapy to replace dystrophin, reporting an
increase in dystrophin-positive myofibers (Mendel et al. 1995; Skuk et al. 2004, 2006,
2007; Rodino-Klapac et al. 2013; Cirak et al. 2012; Seto et al. 2014). While these studies
have successfully reintroduced the protein to dystrophic skeletal muscle, improvements
in function have been limited. A recent study by Hogrel et al. reported a potential longterm effect of a myoblast transplant into an affected female carrier of the dystrophin
mutation. Although long-term functional effects could not be definitively concluded from
this study, the results suggest beneficial effects of cell therapy (Hogrel et al. 2013). To
date, the most commonly used murine model to test cell replacement and other strategies
in a pre-clinical setting has been the mdx mouse, which lacks dystrophin due to an Xlinked mutation in its gene (Partridge et al. 1989; Hindi et al. 2013). Although the mdx
mouse is a genetic homolog of the human disease, it has been shown that this model does
not mimic the pathology observed in patients because up-regulation of utrophin, a
dystrophin analogue, partially compensates for the absence of the cytoplasmic protein
(Grady et al. 1997). Additionally, the longer telomere length present in inbred laboratory
mice confer a greater regenerative capacity of muscle progenitor cells in these animals
compared to human skeletal muscle (Sacco et al. 2010). As a result of these differences,
the disease does not manifest severely in mdx mice. Specifically, fibrosis, a hallmark
feature of DMD in patients, is not overt in mdx mice (Desguerre et al. 2014). A lack of
dystrophin in skeletal muscle leads to decreased sarcolemma integrity, which causes an
increase in cell membrane permeability. As a result, an influx of calcium ions causes
increased protein degradation that eventually leads to muscle cell death. Inflammatory
cells that infiltrate the site of necrosis are a rich source of transforming growth factor beta
(TGFβ). TGFβ then exerts its pro-fibrotic effect on fibroblasts, which then increase

43

production of extracellular matrix (ECM) proteins. An excessive amount of ECM
production leads to the eventual onset of fibrosis (Desguerre et al. 2009). The fact that
DMD patients develop severe fibrosis whereas mdx mice do not may, in part, explain
why treatments performed in murine studies have been ineffective in human trials.
Fibrosis limits the amount of available muscle tissue to target with stem cell, gene or drug
therapy (Bernasconi et al. 1999). Thus, use of an appropriate model that more accurately
reflects the histopathology of DMD fibrosis may better direct current research. Recent
advances in exon-skipping have highlighted the importance of a suitable murine model in
pre-clinical studies. In 2010, Goyenvalle demonstrated an increase in dystrophin
expression in severely affected mice lacking both utrophin and dystrophin following
multiple injections with a morpholino oligomer targeted to exon 23 of the dystrophin
gene (Goyenvalle et al. 2010). Two years later, the same group modified their protocol to
use an adeno-associated virus vector containing a small nuclear RNA specific to exon 23.
A single treatment was sufficient to restore dystrophin in all muscles examined, including
heart tissue, and dramatically increased life expectancy from 10 to 50 weeks of age
(Goyenvalle et al. 2012). These studies have been crucial in highlighting the need for
inclusion of a more accurate DMD mouse model with which to assess the efficacy of
therapeutic strategies.
Although utrophin-dystrophin-deficient (dko) mice were generated in 1997, they are
scarcely used in current studies, perhaps in part due to their severe disease phenotype,
which makes them difficult to include in longitudinal studies. While a select number of
research groups have used this severely affected mouse model, the predominant model
used in today’s research lab is still the mdx mouse. A few studies have suggested that
haploinsufficiency of the utrophin gene (mdx/utrn+/-) may provide a more appropriate
murine model of DMD (Huang et al. 2011). For example, it has been shown that
diaphragm and quadriceps muscles of mdx/utrn+/- mice become fibrotic as early as 3 and
6 months of age, respectively (Zhou et al. 2008). Many studies involving murine models
of DMD have used mice younger than 6 months of age, thus the purpose of this study
was to investigate extent of fibrosis in the mdx/utrn+/- mouse at an earlier age to
determine its suitability as a more accurate representation of the human pathology.
Additionally, since quadriceps and diaphragm muscles were the only groups examined in
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the aforementioned study, we focused our study on the gastrocnemius muscle as it has
often been used as a site of cell implant (Beckman et al. 2013). In the present study, we
examine extent of fibrosis and muscle regeneration in 8 week-old mice as well as aged 10
month-old mice and provide a comprehensive analysis of these parameters in various
skeletal muscles that are used in DMD research.

2.3 Materials and Methods
2.3.1

Animal Care and Ethics Statement

Experiments were performed at The Lawson Health Research Institute at St. Joseph’s
Health Care (SJHC) in London, Ontario. Female C57BL/6 mice (5-7 weeks old upon
arrival) were purchased from Charles Rivers and mdx/utrn+/- mice, originally generated
by Dr.’s Mark Grady and Josh Sanes (Washington University, St. Louis) (Grady et al.
1997), were generously provided to us by Dr. Robert Grange (Virginia Polytechnic and
State University) and maintained in the Animal Care Facility at SJHC. Colonies were
maintained under controlled conditions (19-23˚C, 12 hour light/dark cycles) and allowed
water and food ad libitum. 7 to 8 week-old and 10 month-old male and female C57BL/6,
mdx and mdx/utrn+/- mice were used in this study. Only 7-8 week-old dko mice were
used since these mice do not tend to live past 20 weeks of age. For comparison of various
skeletal muscles, twelve week-old mdx/utrn+/- male and female mice were used. All
procedures involving animal experiments were carried out in strict accordance with the
Canadian Council on Animal Care (CCAC) and were approved by the Animal Use
Subcommittee at Western University.

2.3.2

Genotyping

Genomic DNA from tail snips or ear notch tissue was used for genotyping. Briefly, ear
notch tissue was lysed in a proteinase K solution at 50° C overnight. DNA was diluted
appropriately and polymerase chain reaction was used to amplify the utrophin gene using
Platinum Taq polymerase. Presence of the utrophin gene was detected using the
following set of primers (Sigma): 5’-TGCAGTGTCTCCAATAAGGTATGAAC-3’, 5’-
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TGCCAAGTTCTAATTCCATCAGAAGCTG

-3’

(forward

primers)

and

5’-

CTGAGTCAAACAGCTTGGAAGCCTCC-3’ (reverse primer).

2.3.3

Tissue Preparation and Histology

For tissue collection, mice were sacrificed via gas euthanasia. Diaphragm and
gastrocnemius (GM) muscles from 8 week-old and 10 month-old mice were dissected
and immediately fixed in formalin for 24-48h and embedded in paraffin. For a more
comprehensive analysis of disease manifestation in mdx/utrn+/- mice, diaphragm,
quadriceps, soleus, tibialis anterior (TA) and gastrocnemius (GM) muscles were similarly
isolated from 12 week-old mdx/utrn+/- mice. Extreme care was taken to ensure muscles
were embedded in the same orientation across each muscle group. Tissue blocks were
sectioned at 5um thickness and dried in an oven at 37˚C overnight. To achieve
representative sections from the whole muscle tissue, serial sections were taken every 20
slices, except for the diaphragm muscle where serial sections were taken every 3 slices.
Tissue sections were then deparaffinised and rehydrated in a series of xylene and ethanol
washes to prepare them for subsequent Masson’s Trichrome staining for collagen content,
or haematoxylin and eosin staining to visualize regenerating myofibers. Serial sections
were used for the two staining methods to ensure that analysis of both collagen content
and muscle regeneration referred to the same samples. Following the staining step, slides
were dehydrated, washed in xylene and mounted with Permount mounting medium.

2.3.4

Microscopy and Image Analysis

Histological images were acquired on a Zeiss Axioscope microscope under a 20x
objective using Northern Eclipse software. Non-overlapping fields of view of the entire
tissue were taken for each section. Five sections were imaged per tissue. For assessment
of myofiber damage, percentage of centrally located nuclei was used as an indication of
regeneration. All fields of view containing cross-sectional myofibers were imaged and
manually analyzed. Collagen content was assessed across the entire tissue slice and
automatically quantified using an in-house colour thresholding algorithm written in
MATLAB 2010a (Mathworks, Natick, MA, USA). Briefly, all images were transformed
into Lab colour space allowing the isolation of the colour and lightness components of
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each pixel. A k-means clustering algorithm was then applied to the colour components of
each individual image to partition the pixels into groups of relatively ‘red’ or ‘blue’
colour values (Appendix A). A uniform threshold was applied to all images to mask
regions with high lightness (appearing as white). Finally, morphological closing
operations were performed on the ‘red’ and ‘blue’ regions to fill any gaps less than 3
pixels in radius. The percent of collagen present in each image was calculated as the area
of the remaining ‘blue’ region divided by the area of the entire image. Automatic
thresholds were manually verified with labeled colour overlays on the original histology
images to ensure that collagen presence was accurately identified.

2.3.5

Statistical Analysis

For quantified images, a one-way ANOVA was performed followed by Tukey’s post-hoc
test to determine difference between groups using GraphPad Prism. Differences between
groups were considered significant at a p-value less than 0.05 (n=3 for wild-type and dko
mice and n=5 for mdx and mdx/utrn+/- mice).

2.4 Results
2.4.1

Fibrosis is present at 10 months of age in mdx/utrn+/-, but
not mdx, GM muscle

At ten months of age, mdx gastrocnemius (GM) muscle did not differ in collagen content
compared to GM muscle of wild-type mice (Figure 2.1). In contrast, haploinsufficiency
of utrophin led to significant collagen deposition in GM tissue of aged mdx/utrn+/- mice
(mean±SD: 12.76%±3.06, p=0.0033). There was no significant difference in collagen
deposition between mdx and mdx/utrn+/- GM muscle. Although GM muscles of aged
mdx mice did not show significant fibrosis compared to healthy wild-type controls, there
was a large proportion of centrally-located nuclei in the myofibers indicative of muscle
regeneration in both mdx (70.06%±7.6) and mdx/utrn+/- (58.86%±6.7) mice, respectively
(p<0.0001, Figure 1D-F).
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Figure 2.1: Muscle pathology in 10 month-old GM muscles of wild-type, mdx and
mdx/utrn+/- mice.
Extent of total collagen staining (blue) in 10 month-old wild-type (A), mdx (B) and
mdx/utrn+/- (C) GM muscle was used as a marker of fibrosis. Proportion of centrally
nucleated fibers in the same tissues (D, E, and F) was measured to assess extent of
regeneration. Quantification of total collagen staining (G) and proportion of centrallynucleated myofibers (H) is represented as the mean +SD. ** represents p<0.01, and ***
represents p<0.001 (scale bar=100μm).

48

2.4.2

DMD-associated fibrosis in present in both aged mdx and
mdx/utrn+/- diaphragm muscle

Both mdx and mdx/utrn+/- diaphragm muscles were significantly fibrotic in ten monthold mice compared to age-matched wild-type controls (Figure 2A-C, p=0.026), indicated
by an approximate 2.5 fold increase in collagen content. Both mdx and mdx/utrn+/diaphragm muscle revealed a significantly higher percent of centrally located nuclei
(34.65%±4.4 and 32.45%±5.6, respectively) compared to the age-matched wild-type
mice (p<0.0001). There was no significant difference in number of centrally nucleated
myofibers between mdx and mdx/utrn+/- mice (Figure 2.2).

2.4.3

Young mdx/utrn+/- and dko, but not mdx, GM muscle
develops fibrosis compared to healthy GM muscle

Fibrosis was assessed in 8 week-old GM muscles of wild type, mdx, mdx/utrn+/- and dko
mice (Figure 2.3). There was no observed fibrosis in mdx GM (3.38%±0.9) compared to
wild-type GM (3.40 ±0.2). There was a significantly higher amount of collagen
deposition in mdx/utrn+/- GM (7.28%±2.2) compared to healthy wild-type and mdx
tissue; however this difference was not significant between GM muscles of dko mice
(9.49%±1.5). Overall, quantification of collagen content indicates that fibrosis is absent
in wild-type and mdx GM muscle, but present in mdx/utrn+/- and dko GM muscle at a
young age (p=0.0003). Muscle regeneration was significantly higher in all three murine
models of DMD compared to the wild-type controls (Figure 3E-H). The proportion of
centrally located nuclei did not differ, however, between mdx (50.41%±18.2),
mdx/utrn+/- (49.78%±12.0) and dko GM muscle (45.44%±4.7, p=0.0007).
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Figure 2.2: Muscle pathology in 10 month-old diaphragm muscles of wild-type, mdx
and mdx/utrn+/- mice.
Extent of total collagen staining (blue) in 10 month-old wild-type (A), mdx (B) and
mdx/utrn+/- (C) diaphragms was used as a marker of fibrosis. Proportion of centrally
nucleated fibers in the same tissues (D, E, and F) was measured to assess extent of
regeneration. Quantification of total collagen staining (G) and proportion of centrallynucleated myofibers (H) is represented as the mean +SD. * represents p<0.05 and ***
represents p<0.001 (scale bar=100μm).
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Figure 2.3: Muscle pathology in 8 week-old GM muscles of wild-type, mdx,
mdx/utrn+/- and dko mice.
Extent of total collagen staining (blue) in 8 week-old wild-type (A), mdx (B), mdx/utrn+/(C) and dko (D) GM muscles was used as a marker of fibrosis. Proportion of centrally
nucleated fibers in the same tissues (E, F, G, and H) was measured to assess extent of
regeneration. Quantification of total collagen staining (I) and proportion of centrallynucleated myofibers (J) is represented as the mean +SD. * represents p<0.05, **
represents p<0.01, and *** represents p<0.001 (scale bar=100μm).
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2.4.4

Fibrosis is present in diaphragm muscle at a young age in all
three murine models of DMD

Collagen content in the diaphragm muscle was not determined to be significantly
different between mdx mice (11.04%±2.3) and the two more severely affected animal
models or between healthy wild-type and mdx mice (Figure 4A-D). Collagen deposition
was significantly higher in the diaphragm of both dko (14.17%±4.4) and mdx/utrn+/(13.32%±2.5) mice at 8 weeks of age compared to age-matched wild-type diaphragm
muscle (7.1%±0.3, p=0.0235). Myofiber regeneration was significantly higher in the
diaphragm muscles of mdx (41.48%±6.6) mdx/utrn+/- (39.39%±10.18) and dko
(30.95%±6.4) mice compared to diaphragm muscle in wild-type mice (Figure 2.4,
p<0.0001).

2.4.5

Extent of fibrosis differs between muscle groups in the
mdx/utrn+/- mouse

Diaphragm, quadriceps, soleus, tibialis anterior (TA) and gastrocnemius (GM) muscles
were analyzed from 12 week-old mdx/utrn+/- mice (Figure 2.5). Collagen content in
diaphragm muscle was significantly higher than all other muscles assessed (p<0.0001).
Both the quadriceps (8.31%±0.1) and GM muscles (9.89%±2.4) were higher in collagen
content than the soleus muscle (2.80%±1.0) at this age. Extent of fibrosis was not
significantly different in the TA muscle (5.85%±1.1) compared to the quadriceps, GM or
soleus muscles. Myofiber regeneration, indicated by centrally located nuclei, was
significantly higher in all four lower limb muscles compared to myofibers in the
diaphragm, which only had 35.1% of myofibers in a regenerative state (p<0.0001).
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Figure 2.4: Muscle pathology in 8 week-old diaphragm muscle of wild-type, mdx,
mdx/utrn+/- and dko mice.
Extent of total collagen staining (blue) in 8 week-old wild-type (A), mdx (B), mdx/utrn+/(C) and dko (D) diaphragms was used as a marker of fibrosis. Proportion of centrally
nucleated fibers in the same tissues (E, F, G, and H) was measured to assess extent of
regeneration. Quantification of total collagen staining (I) and proportion of centrallynucleated myofibers (J) is represented as the mean +SD. * represents p<0.05, **
represents p<0.01, and *** represents p<0.001 (scale bar=100μm)
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Figure 2.5: Comparison of histopathology of 12 week-old mdx/utrn+/- diaphragm,
quadriceps, soleus, tibialis anterior and gastrocnemius muscles.
Extent of collagen staining (A,C,E,G,I) and muscle regeneration (B,D,F,H,J) in 12 weekold mdx/utrn+/- mice. Quantification of total collagen staining (K) and centrallynucleated myofibers (CNF, L) is represented as the mean ±SD. * represents p<0.05, **
represents p<0.01, and *** represents p<0.001 (scale bar=100μm). TA= tibialis anterior,
GM= gastrocnemius.
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2.5 Discussion
Fibrosis is a hallmark feature of Duchenne muscular dystrophy (DMD), yet the most
widely- used murine model for the disease, the mdx mouse, does not model this aspect of
DMD until an advanced age (Desguerre et al. 2002). Consistent with previous reports
(Ishizaki et al. 2008), this study demonstrates that while the diaphragm muscle becomes
fibrotic in aged mdx mice hind limb muscle does not. Many studies that investigate the
potential use of stem cell or gene therapy for DMD use hind limb muscles, such as the
gastrocnemius muscle (GM), for sites of injection (Qu-Petersen et al. 2002). Here, we
demonstrate that neither young nor aged mdx mice develop a significant amount of
fibrosis in the GM muscle compared to healthy wild-type controls of the same age. The
fact that mdx mice lack this excessive deposition of extracellular matrix proteins may
lead researchers to overestimate treatment efficacy in this murine model since there is a
lack of environmental hostility when testing their therapeutic agents. Alternatively, the
mdx/utrn+/- mouse exhibits hind limb fibrosis at 10 months of age. Interestingly, a large
proportion of regenerating myofibers, indicative of damage, was measured in both aged
animal models. Centrally located nuclei are a hallmark of muscle regeneration, and are
often used as an indicator of muscle pathogenesis (Anderson et al. 1987). Indeed, while
centric nuclei are prominent in the mdx mouse model of DMD, other aspects of the
disease in humans, particularly fibrosis, are not phenocopied. This may be due, at least in
part, to the up regulation of utrophin in the mdx mouse. As a result, overall muscle
damage is significantly less in mdx mice than in utrophin heterozygotes and double
knockout animals. Interestingly, we have further shown that in muscle tissues exhibiting
higher levels of collagen (e.g. diaphragm), proportions of centric nuclei are lower. In
contrast, the GM muscle in mdx mouse exhibits a significantly higher number of centric
nuclei, but little deposition of collagen. These findings are consistent with earlier reports
hypothesizing that centrally-nucleated myofibers are more resistant to mechanical stress,
which may in part explain for the differences in the pathology observed in diaphragm
versus hind limb skeletal muscles (Narita et al. 1999).
Since DMD manifests at a young age in humans and because most DMD research is
performed in younger animals, we also investigated extent of fibrosis in eight week-old
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mice. Although the GM muscles in young mdx mice are in a regenerative state as
evidenced by the presence of centrally located nuclei, we did not measure a significant
degree of fibrosis in them. In comparison, there was a higher level of collagen measured
in both moderately affected mdx/utrn+/- and severely affected dko mice relative to their
healthy counterparts, suggesting fibrotic progression in these animals. Upon validating
the mdx/utrn+/- mouse as more fibrotic compared to mdx littermates, we sought to
further characterize extent of fibrosis in various muscle groups isolated from the
heterozygous mouse model. As expected, the diaphragm muscle was highly fibrotic
compared to the quadriceps, soleus, tibialis anterior and GM muscles. In comparison,
there was no detectable difference in collagen deposition between the quadriceps, TA or
GM muscles; this is an important finding considering that all three muscles are used in
current research and therefore should display signs of fibrosis (Fletcher et al. 2006,
Church et al. 2014). Interestingly, we measured a lower amount of collagen content in the
slow-twitch soleus muscle than the fast-twitch quadriceps and GM muscles. The fact that
fibrotic progression is not equal between individual skeletal muscles is an important
factor to consider in future studies.
Taken together, this study supports previous literature that argues for the replacement of
the mdx mouse with more severely affected models of DMD, such as the mdx/utrn+/- or
dko mouse (Deconinck et al. 1997a,b). Although dko mice develop debilitating fibrosis at
a young age, these animals do not tend to live past twenty weeks and thus are not
generally used in studies examining the long-term efficacy of a therapeutic intervention.
Similarly, although the diaphragm muscle in all three murine models develops fibrosis at
some point, a more accurate model of DMD should reflect disease manifestation in axial
limbs as well. Nevertheless, it would be optimal for any therapeutic drug under
investigation to show efficacy in the diaphragm muscle since failure of this respiratory
organ is a common cause of death in DMD patients (Bushby et al. 2009, Gilgoff et al.
1989). Since the mdx/utrn+/- mouse develops fibrosis in both hind limb and respiratory
skeletal muscles at a young age while not being so affected such that it dies prematurely,
we provide further evidence here that it may be an appropriate and useful model of DMD.
Furthermore, we report here that this increased disease severity in the mdx/utrn+/- mouse
compared to its mdx counterpart is apparent by two months of age. The mdx/utrn+/-
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mouse is also a suitable precursor model for scaling studies to large animal models of
DMD such as the golden retriever model (GRMD), which exhibits signs of increased
endomysial fibrosis as early as 15 days after birth, with severe fibrosis by 9 months of
age (Passerini et al. 2002; Willmann 2009; Kornegay et al. 2012).
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3

VEGF induces stress fiber formation in fibroblasts
isolated from dystrophic muscle

3.1 Chapter Summary
Although vascular endothelial growth factor (VEGF) has been widely studied as a
possible therapeutic drug to treat DMD, recent work in other fibrotic disease such as
idiopathic pulmonary fibrosis, has revealed a potential role for the growth factor in
exacerbating fibrosis. No study to date has investigated whether VEGF elicits a fibrotic
response in DMD, thus we sought to determine if such an effect might be exerted on
DMD-derived fibroblasts. In this study, we isolated fibroblasts from severely affected
diaphragm and moderately affected gastrocnemius muscles of mdx/utrn+/- mice. The
effect of exogenous VEGF administration on expression of pro-fibrotic genes was
assessed in vitro. The effect of VEGF on stress fiber formation was also assessed. We
used transforming growth factor beta as a positive control in this study since it is a wellknown inducer of a fibrotic response. VEGF did not increase expression of the genes for
type-1 collagen or connective tissue growth factor in either GM- or diaphragm-derived
fibroblasts. Administration of the growth factor did lead to an increase in gene expression
of alpha-smooth muscle actin, but this effect was only observed in diaphragm-derived
fibroblasts and not GM fibroblasts. We also show that VEGF treatment leads to induction
of alpha-smooth muscle actin-positive stress fiber formation indicative of myofibroblast
differentiation. Stress fiber formation occurred in both GM and diaphragm fibroblasts but
the response was more pronounced in diaphragm fibroblasts. The findings of this study
reveal a potential role of VEGF in promoting a fibrotic response in DMD.
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3.2 Introduction
Angiogenic therapy has been proposed as a potential therapeutic agent for treating
skeletal muscle ischemia inherent to Duchenne muscular dystrophy (DMD) (ShimizuMotohashi et al. 2014). To this end, a number of studies have now used a potent inducer
of angiogenesis, vascular endothelial growth factor (VEGF), as a therapeutic agent in the
mdx mouse (Messina et al. 2007; Gregorevic et al. 2004; Beckman et al. 2013).
Importantly, enhanced vascularization in dystrophic muscle has been shown to enhance
the efficacy of regeneration through cell therapy (Bouchentouf et al. 2005). One aspect of
these studies that has not been directly addressed is the effect of exogenous VEGF on
skeletal muscle fibroblasts. Indeed, recent studies indicate that high doses of VEGF
induce fibrosis in inflammatory and non-inflammatory stages of systemic scleroderma
(SSc) (Maurer et al. 2014). Similarly, fibroblasts isolated from patients with idiopathic
pulmonary fibrosis exhibit a decreased fibrotic response following treatment with a
VEGF receptor blocker, nintedanib (Hostettler et al. 2014). The findings in the SSc study
are particularly important because they highlight the differential effect observed with low
levels of circulating VEGF versus high doses of VEGF typically associated with
exogenous treatment. In contrast, studies utilizing murine models of DMD have shown
that a loss of endogenous VEGF may have deleterious effects on regeneration.
Additionally, results from studies that have administered VEGF to dystrophic muscle
have suggested an anti-fibrotic role of the growth factor in this disease. While the latter
findings highlight the immense therapeutic potential of VEGF to treat DMD, there is
currently a lack of studies that directly investigate the effect of exogenous VEGF
treatment on progression of fibrosis (Miyazaki et al. 2011; Rhoads et al. 2013).

Fibrosis develops in DMD patients and is largely responsible for disease fatality
(Desguerre et al. 2009; Chen et al. 2005; Bernasconi et al. 1995). Since the mdx mouse
model does not develop fibrosis to the same extent as is observed in patients, studying the
effect of VEGF on the fibrotic response in this model may lead to an underestimation of
its effect on fibrosis (Desguerre et al. 2012; Zhou et al. 2008). More recent studies have
used a double knockout mutant that lacks both dystrophin and utrophin (dko), but this
mouse is severely affected and does not live past 20 weeks of age (Deconinck et al. 1997;
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Goyenvalle et al. 2010 and 2012; van Putten et al. 2012). We and others have
demonstrated that the heterozygous mdx/utrn+/- mouse develops hind limb skeletal
muscle fibrosis earlier in life than its mdx counterpart, but maintains a longer lifespan of
approximately two years in laboratory conditions (Zhou et al. 2008; Gutpell et al. 2015).
Isolation of primary fibroblasts from this mouse model thus provides a means to directly
assess the effect of exogenous VEGF treatment on the expression of pro-fibrotic genes
(Mezzano et al. 2007). Another important consideration for angiogenic therapy is the
effect of treatment on different muscles affected by DMD. Indeed, all three murine
models of DMD - mdx, mdx/utrn+/- and dko - develop fibrosis in the diaphragm muscle,
and to a greater extent than what is observed in the hind limb musculature of any of these
mice (Stedman et al. 1991; Huang et al. 2011). The underlying mechanism for this
differential progression of fibrosis has not been thoroughly investigated. Therefore, this
study also investigated whether the effect of VEGF treatment differs in diaphragmderived fibroblasts versus gastrocnemius-derived fibroblasts.

3.3 Materials and Methods
3.3.1

Animal Care and Ethics Statement

All experiments were performed at Lawson Health Research Institute at St. Joseph’s
Health Care (SJHC) in London, Ontario. The mdx/utrn+/- mice, originally generated by
Dr.’s Mark Grady and Josh Sanes (Washington University, St. Louis) (Grady et al. 1997),
were generously provided by Dr. Robert Grange (Virginia Polytechnic and State
University) and maintained in the Animal Care Facility at SJHC. Colonies were
maintained under controlled conditions (19–23˚C, 12 hour light/dark cycles) and allowed
water and food ad libitum. Only 10 week-old mdx/utrn+/- mice were used in this study.
All procedures involving animal experiments were carried out in strict accordance with
the Canadian Council on Animal Care (CCAC) and were approved by the Animal Use
Subcommittee at Western University.
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3.3.2

Genotyping

Genomic DNA from tail snips or ear notch tissue was used for genotyping. Briefly, ear
notch tissue was lysed in a proteinase K solution at 50° C overnight. DNA was diluted
appropriately and polymerase chain reaction was used to amplify the utrophin gene using
Platinum Taq polymerase. Presence of the utrophin gene was detected using the
following set of primers (Sigma): 5’-TGCAGTGTCTCCAATAAGGTATGAAC-3’, 5’TGCCAAGTTCTAATTCCATCAGAAGCTG

-3’

(forward

primers)

and

5’-

CTGAGTCAAACAGCTTGGAAGCCTCC-3’ (reverse primer).

3.3.3

Primary Fibroblast Isolation

Gastrocnemius and diaphragm tissue samples were isolated from 10-week old
mdx/utrn+/- mice. The isolation protocol was adapted from a method previously
described by others (Mezzano et al. 2007). Briefly, mice were sacrificed via gas
euthanasia and dissected muscles were placed in sterile phosphate-buffered saline (PBS)
and transferred to a cell culture hood. Tissues were minced into 1-2mm3 pieces and
placed on a gelatin-coated 10cm dish with sterile tweezers. Approximately 20-25 pieces
were plated per dish. The tissue was then covered with primary fibroblast isolation
medium (DMEM/F12 supplemented with 20% FBS plus penicillin and streptomycin) and
incubated at 37°C. By day 4, fibroblasts began exiting the tissue explants. Fibroblast
medium (DMEM/F12 supplemented with 20% FBS and penicillin and streptomycin) was
changed every other day from this point. Cells were passaged at day 7 using 0.25%
trypsin-EDTA. Tissue explants were removed by passing cells through a 100µm nylon
filter. Only cells in passages 2-4 were used for experimental purposes. Fibroblast
population was confirmed by expression of vimentin and matricellular protein CCN2
(Appendix B).

3.3.4

Growth Factor Supplementation

1 x 105 fibroblasts were seeded per well onto a 12-well plate and incubated overnight.
The next day, cells were serum-deprived in reduced-serum fibroblast medium
(DMEM/F12 5% FBS plus penicillin and streptomycin) for 6 hours. Following serum
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deprivation, cells were treated with 50ng/ml recombinant mouse VEGF164 (R&D
Systems), 50ng/ml transforming growth factor–beta (TGFβ), or untreated. Growth factor
doses were determined from previous pilot studies in our lab. TGFβ treatment served as a
positive control for inducing a fibrotic response and the untreated fibroblasts served as a
negative control. Cells were harvested 6 and 18 hours later for subsequent RNA
extraction and 48 hours later for protein extraction.

3.3.5

Quantitative Real-Time Polymerase Chain Reaction

RNA was extracted using a QIAGEN RNeasy Plus Mini Kit. RNA concentration and
quality was assessed using a Nanodrop Spectrophotometer ND-1000. 1-2µg of highquality RNA was reverse-transcribed using the High-Capacity RNA-to-cDNA Kit (Life
Technologies). Following primer validation, Taqman Gene Expression Assays were used
to

measure

Ctgf/ccn2

(Mm01192932_g1),

Col1a1

(Mm00801666_g1),

Acta2

(Mm01546133_m1) and Fn1 (Mm01256744_m1) mRNA expression relative to Gapdh
endogenous control (Mm99999915_g1) levels using the ΔΔCT method on a Real-Time
PCR Applied Biosystems Inc. Prism 7500 under the following conditions: Initial
denaturation at 95ºC for 5 min followed by 40 cycles of denaturation (95ºC for 15 sec),
primer annealing (60ºC for 1 min) and transcript extension (50ºC for 2 min). All samples
were run in triplicate.

3.3.6
Fibroblasts

Immunohistochemistry
were

processed

for

immunocytochemistry

by

fixing

in

2-4%

paraformaldehyde for 20 minutes. Fibroblasts were then washed three times with
phosphate-buffered saline (PBS), and incubated at room temperature in blocking buffer
(1% BSA, 10% goat serum in PBS) for 45 minutes. Fibroblasts were incubated with antiα-SMA (Abcam, 1:100) primary antibody. Following thorough washing with PBS,
Alexafluor 488-IgG (Life Technologies, 1:1000) secondary antibody was used to
visualize the primary antibody, and ProLong Gold anti-fade with DAPI (Life
Technologies) was added to visualize the nuclei and to mount the coverslips onto glass
slides. Fluorescent images were acquired at a twenty times magnification on a Nikon
Eclipse microscope.
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3.3.7

Western Blot

Cells were collected in Phosphosafe lysis buffer containing a protease inhibitor cocktail
and lysed via sonication. Cell culture supernatants were collected and lyophilized for 210
minutes at 45°C and re-suspended in PBS. Protein was quantified using the bicinchoninic
acid assay (Pierce). 50μg of protein was heat denatured and loaded onto a TGX stain-free
SDS gel. Protein was transferred onto a PVDF low fluorescence membrane using the
Transblot Turbo machine (Bio-Rad) and total protein was visualized on the Bio-Rad Gel
Doc system. Membranes were blocked with 5% bovine serum albumin in tris-buffered
saline containing 0.05% tween 20 for 1 hour. Blots were then incubated with primary
anti-fibronectin antibody (1:1000, Abcam) at 4°C overnight.

Following thorough

washing in TBS-T, blots were incubated with anti-rabbit HRP secondary antibody
(1:5000) for 1 hour. Bands were visualized via chemiluminescence using ImageLab
software (Bio-Rad) and normalized to total protein signal from the stain-free blots
(Taylor et al. 2013). Bands from cell culture supernatants are shown for qualitative
purposes only since normalization to total protein was not possible given the signal
saturation from the serum.

3.3.8

Statistical Analysis

Gene expression data was analyzed using a two-way analysis of variance (ANOVA) to
determine simple main effects of treatment and time point followed by individual oneway ANOVA to assess differences within the 6- and 18-hour time points. Differences
between groups were determined using Tukey’s post-hoc test. A p-value less than 0.05
was considered significant (n=6 and n=4 for gene expression and protein experiments,
respectively).

3.4 Results
3.4.1

Effect of VEGF on Fibrotic Gene Expression

Expression of multiple genes involved in dysregulated tissue repair was measured to
investigate whether VEGF induces a fibrotic response in fibroblasts derived from
dystrophic muscle. Specifically, changes in mRNA levels of Ctgf/ccn2, Col1a1, Fn1, and
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Acta2, were assessed in diaphragm and GM-derived fibroblasts. TGFβ increased
expression of Ctgf/ccn2 in both GM- and diaphragm-derived fibroblasts. Six hours
following administration, a 4.6- and 14.2-fold increase in expression of the gene was
measured in GM (p<0.0001) and diaphragm fibroblasts (p=0.0002), respectively (Figure
3.1). This level of Ctgf/ccn2 expression was significantly higher than expression in either
control fibroblasts or VEGF-treated fibroblasts. There was no measureable increase in
Ctgf/ccn2 transcript level following VEGF treatment in either diaphragm or GM
fibroblasts. The gene that encodes the pro-alpha(I) chain of type-1 collagen, was assessed
to represent changes in collagen expression (Figure 3.2). TGFβ led to significantly higher
expression of Col1a1 in GM fibroblasts compared to either control or VEGF-treated GM
fibroblasts. In diaphragm fibroblasts Col1a1 expression was higher in TGFβ-treated
fibroblasts compared to controls, but not higher than in VEGF-treated fibroblasts.
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Figure 3.1: VEGF does not increase expression of Ccn2/ctgf in fibroblasts derived
from GM or diaphragm muscle of mdx/utrn+/- mice.
Fibroblasts isolated from gastrocnemius (top) or diaphragm muscles (bottom) of
mdx/utrn+/- mice were treated with VEGF164 for 6 or 18 hours. Treatment with TGFβ, a
known-inducer of pro-fibrotic gene expression, was used as a positive control. Ctgf/ccn2
expression levels were measured relative to Gapdh (n=6). * and † denote significant
difference between groups within the 6 and 18 hour time points, respectively. **p<0.01,
***p<0.001, ****p<0.0001 +SD.
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Figure 3.2: VEGF does not increase expression of Col1a1 in fibroblasts derived from
GM or diaphragm muscle of mdx/utrn+/- mice.
Fibroblasts isolated from gastrocnemius (top) or diaphragm muscles (bottom) of
mdx/utrn+/- mice were treated with VEGF164 for 6 or 18 hours and expression of
Col1a1 was assessed via qPCR. Treatment with TGFβ, a known-inducer of pro-fibrotic
gene expression, was used as a positive control. Col1a1 expression levels were measured
relative to Gapdh (n=6), * and † denote significant difference between groups within the
6 and 18 hour time points, respectively **p<0.01, ***p<0.001, +SD
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3.4.2

Effect of VEGF on fibronectin expression

To determine if VEGF stimulates expression of genes that encode the extracellular matrix
protein fibronectin, we assessed changes in mRNA expression of Fn1. Neither TGFβ nor
VEGF altered expression of Fn1 by any time points assessed in this study (Figure 3.3).
Conversely, Western blot analysis of fibronectin protein (FN) confirmed that VEGF, but
not TGFβ, increased expression of the protein by 1.9-fold in diaphragm fibroblasts
(p=0.029) and by 1.5-fold in GM fibroblasts (p=0.001). Similar qualitative trends were
observed in FN levels in the supernatant (Figure 3.4).

3.4.3

Changes in αSMA Expression Following VEGF Treatment

Acta2 expression significantly increased in GM-derived fibroblasts 1.8-fold following
TGFβ treatment, but not following VEGF treatment (Figure 3.5). Acta2 expression in
diaphragm-derived fibroblasts, on the other hand, responded to both TGFβ treatment as
well as VEGF treatment. TGFβ induced a 1.5-fold increase compared to control cells as
early as 6 hours after administration of the growth factor. By 18 hours, Acta2 expression
was 1.9- and 1.5-fold higher in fibroblasts treated with TGFβ and VEGF, respectively
(p<0.0001). Immunocytochemical analysis revealed minimal αSMA expression in both
GM and diaphragm fibroblasts. While all αSMA protein expressed in untreated GMfibroblasts was located in the cytoplasm (Figure 3.6), some untreated αSMA-positive
diaphragm fibroblasts expressed the protein within stress fibers (Figure 3.7). TGFβ
induced a robust response in diaphragm fibroblasts resulting in high levels of αSMA
expression. Myofibroblast differentiation in these cells was evident by stress fiber
formation. A similar, but less striking, response was observed in diaphragm fibroblasts
treated with VEGF, as a large portion of these cells also underwent stress fiber formation.
GM-derived fibroblasts appeared to respond to both TGFβ and VEGF, although the
response was more subdued compared to the one observed in diaphragm fibroblasts.
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GM#

Diaphragm#

Figure 3.3: Fn1 expression in is not altered by VEGF or TGFβ in fibroblasts
isolated from either GM or diaphragm muscles of mdx/utrn+/- mice.
Fibroblasts isolated from gastrocnemius (top) or diaphragm muscles (bottom) of
mdx/utrn+/- mice were treated with VEGF164 for 6 or 18 hours. Treatment with TGFβ, a
known-inducer of pro-fibrotic gene expression, was used as a positive control. Fn1
expression levels were measured relative to Gapdh (n=6), *significant difference between
treatment groups within the 6 hour time point, †significant difference between groups
within the 18 hour time point.
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Figure 3.4: FN levels are increased following treatment of diaphragm and GM
fibroblasts with VEGF.
Western blot analysis (A) reveals an increased level of intracellular FN and extracellular
FN located in the cell culture supernatant following 48 hours in the presence of VEGF164.
FN levels from cell lysates of diaphragm (B) and GM (C) fibroblasts were measured
relative to total protein (n=4, *p<0.05, **p<0.01).
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Figure 3.5: VEGF increases Acta2 expression in diaphragm, but not in GM
fibroblasts derived from mdx/utrn+/- mice.
Fibroblasts isolated from gastrocnemius (top) or diaphragm muscles (bottom) of
mdx/utrn+/- mice were treated with VEGF164 for 6 or 18 hours. Treatment with TGFβ, a
known-inducer of pro-fibrotic gene expression, was used as a positive control. Acta2
expression levels were measured relative to Gapdh (n=6), *significant difference between
treatment groups within the 6 hour time point, †significant difference between groups
within the 18 hour time point. *p<0.05, **p<0.01, ±SD.
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Figure 3.6: VEGF induces stress fiber formation in GM fibroblasts indicative of
myofibroblast differentiation.
GM fibroblasts were treated with VEGF164 for 48 hours. Treatment with TGFβ, a knowninducer of pro-fibrotic protein expression, was used as a positive control. Alpha-smooth
muscle actin (αSMA), a marker of myofibroblasts, is shown in green. DAPI (blue) was
used as a counterstain (scale bar= 50µm).
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Figure 3.7: VEGF induces stress fiber formation in diaphragm fibroblasts indicative
of myofibroblast differentiation.
Diaphragm fibroblasts were treated with VEGF164 for 48 hours. Treatment with TGFβ, a
known-inducer of pro-fibrotic protein expression, was used as a positive control. Alphasmooth muscle actin (αSMA), a marker of myofibroblasts, is shown in green. DAPI
(blue) was used as a counterstain (scale bar= 50µm). Although some untreated control
fibroblasts are αSMA-positive, treatment with either TGFβ or VEGF led to greater
expression of the protein in stress fibers.

77

3.5 Discussion
Therapeutic approaches to slow or attenuate the degenerative effects of DMD include
attempts to restore dystrophin, the cytoskeletal protein that is missing or aberrant in DMD
patients (Pessina et al. 2014). Gene and stem cell therapies are but two approaches
currently under intense investigation to serve this purpose, but both of these are limited
by the hostile microenvironment where regenerative therapy needs to occur. Skeletal
muscle in both patients and animal models of DMD is poorly vascularized, leading to
studies exploring the use of pro-angiogenic therapies to enhance the ischemic
microenvironment (Arsic et al. 2004; Borselli et al. 2010). VEGF is a particularly
attractive candidate for such a therapy since it is a well-known, potent inducer of
angiogenesis. Although the literature currently suggests that VEGF enhances cell
engraftment in the mdx mouse (Messina et al. 2007; Deasy et al. 2009), it remains to be
determined whether VEGF induces a fibrotic response in DMD. In fact, a reduction in
fibrosis following delivery of muscle-derived stem cells overexpressing VEGF has been
shown in the mdx GM muscle (Deasy et al. 2009). The main motivation for this study
was the findings from recent studies that examined the effect of VEGF in other fibrotic
diseases such as SSc and idiopathic pulmonary fibrosis, whereby elevated levels of
VEGF increased markers of fibrosis. In contrast, inhibition of VEGF was shown to have
an anti-fibrotic effect (Maurer et al. 2014; Hostettler et al. 2014). These studies highlight
the need to assess angiogenic therapy for the treatment of DMD in an animal model that
develops significant fibrosis. Since the mdx mouse does not develop fibrosis as severely
and early as DMD patients (Konieczny et al. 2013), our study focused on investigating
the effect of VEGF on fibroblasts derived from a more fibrotic mouse model of DMD,
the mdx/utrn+/- mouse (Zhou et al. 2008). Furthermore, since most studies to date have
focused on the effect of VEGF on the hind limb muscles, our second objective was to
determine whether there is a differential response to VEGF in diaphragm and
gastrocnemius fibroblasts. To this end, gene expression analyses in the present study have
indicated that VEGF treatment may alter expression of some genes involved in the
fibrotic response, specifically Acta2, the gene that encodes αSMA. Expression of the
genes that encode CTGF/CCN2 and collagen were not altered by VEGF, however these
findings were inconclusive since we did not further investigate the levels of these two

78

proteins following treatment. Visualization of αSMA expression in VEGF-treated cells
suggests a role for this growth factor in promoting differentiation of these fibroblasts,
particularly ones derived from the diaphragm, into myofibroblasts.

Although Fn1 levels were not affected by either treatment, protein levels of FN increased
in the presence of VEGF, but not TGFβ. It is perhaps not surprising that exogenous TGFβ
did not stimulate increased FN levels compared to the control treatment since all cells in
this study were derived from mdx/utrn+/- mice. Previous work has demonstrated that
conditioned media from mdx fibroblasts stimulates a fibrotic response, including
increased FN, in wild-type fibroblasts (Mezzano et al. 2007). Given these findings, it may
be that untreated fibroblasts in the present study also secreted pro-fibrotic factors into the
culture medium, leading to an increase in FN even in the absence of exogenous TGFβ.
Thus, the finding that exogenous VEGF treatment increased FN levels in our study is
particularly intriguing. Since VEGF treatment resulted in increased FN protein but did
not alter mRNA expression, it appears that VEGF may act translationally or posttranslationally to enhance FN expression in mdx/utrn+/- fibroblast cultures. The fact that
VEGF treatment led to increased FN both in cell lysates and cell culture supernatant
warrants further investigation. This finding is consistent with work in other animal
models of disease such as preclinical diabetic retinopathy whereby exogenous VEGF
injection to a rat retina induced expression of FN as well as other fibrotic markers
(Kuiper et al. 2007). That VEGF only affected protein, but not mRNA, levels in the
present study also warrants further analysis. Since only two time points were assessed
here, looking at FN mRNA expression over a time course may yield different results than
those attained in this study. Interestingly, work over the past decade has revealed binding
sites for VEGF on full length fibronectin and these studies have suggested that, in this
case, the binding of these two proteins in the ECM act to increase the biological activity
of VEGF (Wijelath et al. 2002, 2004; Goerges and Nugent 2004; Vempati et al. 2014).
Further, it is well known that loss of FN negatively impacts vasculogenesis and
angiogenesis due, in part, to the decrease in VEGF activity (Astrof and Hynes 2009).
Although previous work highlights an important interaction between FN and VEGF, our
results are the first to show a potential effect of VEGF on FN expression. As such, the
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role of this interaction in the context of angiogenesis in dystrophic muscle also warrants
further detailed investigation.

Given that diaphragm and GM muscles in mdx/utrn+/- mice display different abilities to
develop fibrosis, we investigated whether fibroblasts from these different muscles also
respond differently to VEGF treatment. Although the two cell types showed similar gene
expression profiles following treatment, there were a few key differences observed here.
First, untreated diaphragm fibroblasts appear to be more myofibroblast-like than GM
fibroblasts, as evidenced by the presence of αSMA stress fibers, which were rare in the
GM fibroblast cultures. Further, TGFβ stimulated a more drastic response in diaphragm
fibroblasts compared to GM fibroblasts, evidenced by higher αSMA expressed and more
prominent stress fiber formation. A similar trend was observed following VEGF
treatment, although not to the same extent as observed following TGFβ administration.
These findings suggest that fibroblasts from different muscles may respond in a unique
way to various growth factors. As such, further work will be needed to determine whether
diaphragm-derived fibroblasts indeed respond differently to VEGF treatment than do
hind limb muscles. Since the pathology progression is more rapid in the diaphragm than
hind limb muscles, considering the effect of treatment on both of these muscles will be
crucial for future work.
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4

Vascular-targeted therapy attenuates ischemia and
fibrosis in DMD mice

4.1 Chapter Summary
A number of limitations currently surround the use of vascular-targeted therapy to treat
DMD. The previous chapters describe the use of a murine model that develops more
fibrosis than the mdx mouse. Results from chapter 2 indicate the mdx/utrn+/- mouse, a
model that lacks dystrophin and is heterozygous for utrophin, exhibits more collagen
deposition at an early age compared to its mdx counterpart. Using the mdx/utrn+/- mouse,
chapter 3 demonstrated a potential role of VEGF in eliciting a fibrotic response in vitro in
fibroblasts derived from the diaphragm and, to a lesser extent, the gastrocnemius muscles
from this murine model. It is not well known whether VEGF alone induces functional
changes in perfusion in a relevant murine model of DMD or if another factor,
angiopoietin-1 (ANG1), is also necessary. Further, whether VEGF exerts a pro-fibrotic
effect has not been confirmed in vivo. Using dynamic contrast-enhanced computed
tomography (DCE-CT) to measure perfusion, we show that functional perfusion
decreases over a two week period and that blood flow and blood volume are unaffected
by localized delivery of VEGF alone compared to sham-injected controls. In contrast,
mice treated with a combination of VEGF and ANG1, exhibit reduced progression of
ischemia over the treatment period, evidenced by a lesser reduction in blood volume
compared to either the sham- or VEGF-treated mice. These vascular differences are
validated histologically by increased vessel maturation in hind limb muscles that received
the combination treatment. There is also histological evidence that VEGF and ANG1
treatment resulted in reduced infiltration of leukocytes into the muscle tissue and reduced
deposition of collagen in the endomysium.
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4.2 Introduction
Vascular-targeted therapy to treat Duchenne muscular dystrophy (DMD) has been
investigated since the early 2000’s (Shimizu-Motohashi et al 2014). The proposed
mechanisms by which angiogenic therapy may alleviate the pathophysiology associated
with DMD are numerous. Previous work has provided evidence of compromised
vasculature in the disease, including impaired angiogenesis (Palladino et al 2013) and
decreased vascular density in the mdx mouse, the most widely used murine model of
DMD (Loufrani et al 2004), as well as in the gold-retriever model of (Nguyen et al 2005).
As such, many groups have attempted to increase vascular density in dystrophic muscle
by treating it with vascular endothelial growth factor (VEGF), a well-known and potent
inducer of angiogenesis (Messina et al. 2007; Gregorevic et al. 2004; Beckman et al.
2013). Histological markers of endothelial cells, cells that make up the luminal wall of
vessels, demonstrate increased vascular density following VEGF treatment. Other studies
have also shown that VEGF levels are decreased in some muscle groups in mdx mice as
well as in patients (Abdel-Salam et al 2009). These findings are somewhat inconclusive,
though, as others have shown that VEGF levels are increased in dystrophic muscle tissue.
This discrepancy is likely due to a temporally dependent alteration in VEGF expression
at various stages of the disease. Interestingly, hypoxia-inducible factor-1 alpha (HIF1-α)
is increased in DMD patients (Abdel-Salam et al 2010) and others have shown that
increases in HIF1-α in the mdx mouse brain correspond to elevated levels of VEGF (Nico
et al 2007).
Although promising results have been shown regarding the use of VEGF to
alleviate ischemia, there are a number of questions that remain unanswered. First, it has
been widely proposed that VEGF, while inducing angiogenesis, creates only immature
and “leaky” vessels that do not confer significant functional benefit to the muscle
(Gavard et al 2008). Although histological analyses have revealed an increase in vascular
density following VEGF treatment, whether these newly formed vessels are functional
has not been rigorously investigated. Groups have therefore begun to use VEGF in
combination with other factors, particularly angiopoietin-1 (ANG1), to induce vascular
maturation (Chae et al 2000; Shyu et al 2003; Yamauchi, et al 2003 Chen et al 2007).
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Binding of ANG1 to the Tie2 receptor on endothelial cells activates the receptor’s
tyrosine kinase activity, producing a cellular response that results in vessel survival and
stabilization (Fukuhara et al 2010). Receptor activation increases phosphatidylinositol 3kinase (PI3K) activity, leading to stimulation of AKT, a cell survival signaling molecule
that inhibits transcription factors essential in vascular destabilization (Daly et al., 2004).
Activation of the PI3K pathway also increases expression of survivin, an inhibitor of
apoptosis in endothelial cells (Papapetropoulos et al., 2000). Upon Tie2 activation,
vascular-endothelial cadherin increases adhesion between endothelial cells, lending to an
increase in overall vessel stability (Gamble et al., 2000; Gavard et al 2008). Importantly,
ANG1 recruits vascular smooth muscle cells by signaling through endothelial cells
(Iivanainen et all 2003, Kobayashi et al 2006). This vascular smooth muscle lining
ultimately confers functional maturity to newly formed vasculature (Brudno et al 2013).
Given the role of VEGF and ANG1 in angiogenesis, various groups have
attempted to exploit their function as a vascular-targeted approach to treating ischemia in
DMD (Mofarrahi et al 2015). Indeed, VEGF administration has been shown to increase
endogenous repair and enhance the efficacy of transplanted cell populations. Still,
questions remain regarding the reality of using these factors to treat DMD. Importantly,
very little data exists describing the functional efficacy these factors exert in a
longitudinal manner in DMD models. Position emission tomography demonstrates that
blood flow is not affected by VEGF treatment alone in the rat skeletal muscle, but is
significantly increased when VEGF is combined with ANG1 (Zaccigna et al 2007). Thus,
the objective of the present study is to non-invasively assess the effect of VEGF
treatment alone or in combination with ANG1 on functional angiogenesis in dystrophic
murine hind limb skeletal muscle. Our group has previously reported the use of dynamic
contrast-enhanced computed tomography (DCE-CT) to monitor disease progression in
murine models of DMD (Ahmed et al 2011), but no study to date has attempted to assess
therapeutic intervention in preclinical studies using this imaging modality. Further, we
utilize the mdx/utrn+/- mouse, a model that lacks dystrophin and is heterozygous for
utrophin, a dystrophin analogue. Previous studies have suggested the heterozygous mouse
as a superior model for DMD research since this mouse develops fibrosis to a greater
extent compared to the dystrophin-null mdx mouse (Zhou et al 2008). Using the
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mdx/utrn+/- mouse, which is more prone to fibrosis, is of particular importance given
recent findings showing a potential role of VEGF in exacerbating disease severity in
other fibrotic diseases such as scleroderma and idiopathic pulmonary fibrosis (Maurer et
al. 2014 & Hostettler et al. 2014). Additionally, long-term overexpression of VEGF
promotes fibrosis in skeletal muscle in the ischemic hind limb rabbit model (Karvinen et
al 2011).

4.3 Materials and Methods
4.3.1

Animal Care and Ethics Statement

Experiments were performed at The Lawson Health Research Institute at St. Joseph’s
Health Care (SJHC) in London, Ontario. Heterozygous mdx/utrn+/- mice, originally
generated by Dr.’s Mark Grady and Josh Sanes (Washington University, St. Louis) [12],
were generously provided to us by Dr. Robert Grange (Virginia Polytechnic and State
University) and maintained in the Animal Care Facility at SJHC. Colonies were
maintained under controlled conditions (19-23˚C, 12 hour light/dark cycles) and allowed
water and food ad libitum. Nine to ten week-old male mice were used in this study. All
procedures involving animal experiments were carried out in strict accordance with the
Canadian Council on Animal Care (CCAC) and were approved by the Animal Use
Subcommittee at Western University.

4.3.2

Genotyping

Genomic DNA from tail snips or ear notch tissue was used for genotyping. Briefly, ear
notch tissue was lysed in a proteinase K solution at 50° C overnight. DNA was diluted
appropriately and polymerase chain reaction was used to amplify the utrophin gene using
Platinum Taq polymerase. Presence of the utrophin gene was detected using the
following set of primers (Sigma): 5’-TGCAGTGTCTCCAATAAGGTATGAAC-3’, 5’TGCCAAGTTCTAATTCCATCAGAAGCTG

-3’

(forward

CTGAGTCAAACAGCTTGGAAGCCTCC-3’ (reverse primer).

primers)

and

5’-
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4.3.3

Enzyme-linked immunosorbent assays

To determine endogenous levels of VEGF and ANG1, we used a Quantikine Mouse
VEGF kit (R&D Systems) and a Mouse ANG1 ELISA kit (Lifespan Biosciences). 10
week-old mdx/utrn+/- mice (n=6) and C57Bl10 (n= 6) were euthanized. Dissected tissue
was placed in ice cold PBS, homogenized and stored overnight at -20 ° C to ensure
complete lysis of homogenates. Samples were then centrifuged at 5000xg for 5 minutes
and only the supernatant assayed. Total protein was quantified using the BCA Assay
(Pierce) prior to ELISA assay. All samples were run in duplicate and absorbance was
measured at 450nm.

4.3.4

Local Delivery of Growth Factors

Affi-Gel Blue Beads (BioRad) were air-dried in a cell culture hood under sterile
conditions overnight. The next day, beads were resuspended in 10μl of: sterile phosphatebuffered saline (PBS), 0.5μg recombinant mouse VEGF, 5μg recombinant human ANG1,
or a combination of VEGF and ANG1. Beads were incubated in the growth factors
overnight. The next day, beads were centrifuged for 5 minutes at 12,000rpm, the
supernatant was removed and the beads were re-suspended in 10μl sterile PBS. Hind limb
hair was gently plucked and the exposed skin was wiped with isopropyl alcohol to ensure
sterility. The beads were implanted intramuscularly into the posterior compartment of the
hind limb (lateral head of the gastrocnemius muscle) as follows: mice in the “sham”
group received PBS-soaked beads in both hind limbs, “VEGF” mice received PBSsoaked beads in the right hind limb and VEGF-coated beads in the left, and the
“VEGF+ANG1” group received VEGF-coated beads in the right hind limb and
VEGF+ANG1-coated beads in the left. Injections took place before the anatomical axial
CT scan while the mouse was anesthetized.

4.3.5

Dynamic Contrast-Enhanced Computed Tomography

Mice were scanned at baseline and 2 weeks post-injection (time point based on pilot
studies previously conducted in our lab, Appendices C,D). During each imaging session,
anesthesia was induced with 3% isofluorane and maintained with a 1.5% oxygenbalanced isofluorane mixture, delivered at a constant rate of 1L/min. DCE-CT protocol
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was adapted from a previous study (Ahmed et al. 2011). Briefly, following an anatomical
axial scan, each mouse received 200 μL of Conray 43 contrast agent (diluted 1:2 with
saline) at an injection rate of 2.0 ml/min with an infusion pump (New Era Pump Systems
Inc) via tail vein catheter. CT Perfusion software (GE Healthcare) was used to quantify
blood flow (BF) and blood volume (BV) based on functional maps from the acquired
series of CT images (Cenic A, et al., 1999). Perfusion data acquired for each mouse was
normalized to baseline values to minimize biological variability between animals, thus
allowing us to assess longitudinal changes between groups. Regions of interest were
drawn around the whole cross-sectional slice of the hind limb, excluding the tibia and
fibula, and three slices covering the leg were included in each calculation (Appendix E).

4.3.6

Tissue Preparation

At the end of the imaging study, mice were sacrificed via gas euthanasia followed by
cervical dislocation. Gastrocnemius and diaphragm muscles were dissected, immediately
fixed in formalin, and embedded in paraffin. Extreme care was taken to ensure muscles
were embedded in the same orientation across each muscle group. Tissue blocks were
sectioned at 5um thickness and dried in an oven at 37˚C overnight. To achieve
representative sections from the whole muscle tissue, serial sections were taken every 20
or 5 slices for the GM and diaphragm muscles, respectively. Tissue sections were then
deparaffinised and rehydrated in a series of xylene and ethanol washes to prepare them
for subsequent Masson’s Trichrome staining for collagen content (performed at the
Pathology Department at University Hospital, London, ON), or haematoxylin and eosin
staining to visualize inflammation. Serial sections were used for the two staining methods
to ensure that analysis of both collagen content and inflammation referred to the same
samples. Following the staining step, slides were dehydrated, washed in xylene and
mounted with Permount mounting medium.

4.3.7

Immunohistochemistry

Tissue sections were processed for immunocytochemistry by deparaffinising and
rehydrating sections followed by heat-mediated antigen retrieval in a citrate buffer for 20
minutes. Slides were then cooled slowly to room temperature and incubated in blocking
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buffer (1% BSA, 10% goat serum in PBS) for one hour. Sections were incubated with
anti-αSMA (Abcam, 1:100) or anti-CD45 (Abcam, 1:50) primary antibodies at 4°C
overnight. Following thorough washing with PBS, Alexa Fluor IgG (Life Technologies,
1:1000) secondary antibodies were used to visualize the primary antibodies, and ProLong
Gold anti-fade with DAPI (Life Technologies) was added to visualize the nuclei and to
mount the coverslips onto glass slides. Fluorescent images were acquired on a Nikon
Eclipse microscope.

4.3.8

Microscopy and Image Analysis

For Masson’s Trichrome sections, colour histological images were acquired on a Zeiss
Axioscope microscope under 10x objective using Northern Eclipse software. Nonoverlapping fields of view of the entire tissue were taken for each section. Collagen
content was assessed across the entire tissue slice and automatically quantified using an
in-house colour thresholding algorithm written in MATLAB 2015b (Mathworks, Natick,
MA, USA) designed to separate red and blue image components as previously described
(Gutpell et al. 2015). The percentage of each slide area positive for collagen presence was
calculated, and automatic thresholds were manually verified with labeled colour overlays
on the original histology images to ensure that collagen presence was accurately
identified.
For αSMA and CD45 sections, grey scale fluorescence images were acquired on a Nikon
Eclipse Microscope using NIS Elements Microscope Image Software. Non-overlapping
fields of view of the entire tissue were taken for each section. A semi-automatic grey
scale thresholding algorithm was implemented in MATLAB 2015a to quantify the area of
each slide positive for αSMA or CD45 while mitigating variations due to image exposure
and auto-fluorescence; referred to as “background” intensity variations. The three major
steps of the algorithm are 1) background intensity estimation, 2) stain identification, and
3) stain area calculation. These steps are briefly described as follows. 1) The intensity
gradient magnitude of each slide was calculated, and contiguous regions with a gradient
magnitude less than a constant threshold were assigned as background. This background
threshold was empirically selected as 40 intensity units, or roughly 8% of the maximum
signal intensity gradient observed across slides. 2) All closed non-background regions
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with maximum signal intensity greater than a stain threshold were assigned positive for
stain presence. The stain threshold was manually selected as either 4× or 5× times the
mean background signal intensity of each slide. 3) Within each closed non-background
region considered positive for stain presence, the final stained area was determined by
applying a threshold of 25% of the maximum intensity in that region. The percentage of
total area positive for stain was calculated for each slide. Again, automatic thresholds
were manually verified using labeled colour overlays on the original images, and any
features incorrectly identified as positive for stain were manually edited.

4.3.9

Western Blot

Tissue was collected in Phosphosafe lysis buffer (EMD Millipore) containing a protease
inhibitor cocktail (EMD Millipore) and homogenized. Protein was quantified using the
bicinchoninic acid assay (Pierce). 25 μg of protein was heat denatured and loaded onto a
TGX stain-free SDS gel. Protein was transferred onto a PVDF low fluorescence
membrane using the Transblot Turbo machine (Bio-Rad) and total protein was visualized
on the Bio-Rad Gel Doc system. Membranes were blocked with 5% bovine serum
albumin in Tris-buffered saline containing 0.05% Tween 20 for 1 hour. Blots were then
incubated with primary αSMA (1:1000, Abcam) or anti-CD45 (1:500, Abcam) primary
antibodies at 4°C overnight.

Following thorough washing in TBS-T, blots were

incubated with anti-rabbit or anti-mouse horseradish peroxidase secondary antibodies
(1:5000) for 1 hour. Bands were visualized via chemiluminescence using ImageLab
software (Bio-Rad) and normalized to total protein signal from the stain-free blots
(Taylor et al. 2013).

4.3.10

Statistical Analysis

Data was analyzed using Student’s t-test for ELISA results and an analysis of variance
(ANOVA) for the perfusion and histology results. Differences between groups were
determined using Tukey’s post-hoc test. A p-value less than 0.05 was considered
significant. Replicate values for each experiment are presented with the results.
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4.4 Results
4.4.1

Endogenous levels of both VEGF and ANG1 are significantly
reduced in severely fibrotic diaphragm tissue, but not weakly
affected GM tissue of the mdx/utrn+/- mouse

Endogenous expression of VEGF and ANG1 was measured in the diaphragm and GM
muscles at 9-10 weeks of age (Figure 4.1). The level of VEGF in GM muscle of
mdx/utrn+/- mice (19.6pg/ml) was similar to that measured in wild-type mice
(19.3pg/ml, p=0.93). However, compared to healthy diaphragm muscle (63.0pg/ml), the
concentration of VEGF in dystrophic diaphragm muscle (39.2pg/ml) was significantly
reduced (p=0.0049). A similar trend was observed for the endogenous concentration of
ANG1 in healthy versus dystrophic diaphragm and GM muscles. Specifically, ANG1
expression in healthy and dystrophic GM muscles was 85.3 and 54.1 pg/ml, respectively,
but these values were not determined to be significantly different from one another
(p=0.09). In contrast, a marked reduction of ANG1 expression was measured in the
diaphragm of dystrophic mice relative to wild-type controls (148.3 and 365.6 pg/ml,
respectively; p<0.0001).
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A

B

Figure 4.1: VEGF and ANG1 are decreased in dystrophic diaphragm and murine
muscles.
ELISA analysis of VEGF and ANG1 in 9 to 10 week-old mdx/utrn+/- diaphragm and
GM muscles compared to healthy wild type controls. A. VEGF was lower in mdx/utrn+/diaphragm muscles compared to healthy wild-type controls. VEGF expression was not
significantly different between dystrophic and healthy GM muscles. B. ANG1 was lower
in mdx/utrn+/- diaphragm muscles compared to healthy wild-type controls. ANG1
expression was not significantly different between dystrophic and healthy GM muscles.
n = 6 per group, *P < 0.05, by Student’s t-test. Error bars represent SD.
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4.4.2

Effect of VEGF and ANG1 on perfusion

Blood flow (BF) and blood volume (BV) were assessed as parameters of perfusion in this
study. There was no significant difference measured between the two hind limbs,
regardless of treatment. BF and BV are therefore presented as fold change averages
between the two limbs after 16 days of growth factor treatment (Figure 4.2). Absolute
values for BF and BV indicate that measurements were not significantly different among
mice in different treatment groups at baseline (Table 4.1). Baseline values also indicate
the degree of variability between mice. BF decreased in all mice, regardless of treatment,
over the course of the study (Figure 4.3). There was no significant difference in BF fold
change

between

sham-injected

(0.417±0.26),

VEGF-treated

(0.408±0.17),

and

VEGF+ANG1-treated mice (0.979±0.64; p= 0.0614). BV also decreased over the twoweek period, but the change was less marked in mice that received the combination
treatment of VEGF+ANG1 (0.847±0.40) compared to either the sham-injected control
(0.284±0.12) or VEGF-treated groups (0.398±0.16; p= 0.0109). No significant difference
in BV fold change was measured between the sham-injected and VEGF-treated mice
(Figure 4.4).

4.4.3

VEGF and ANG1 increase vessel maturation in
gastrocnemius muscle of mdx/utrn+/- mice

Western blot analysis was employed to assess total alpha-smooth muscle actin (αSMA) in
GM tissue homogenates following the two-week treatment period (Figure 4.5). Total
αSMA expression was increased in GM muscles from VEGF+ANG1 treated mice
compared to controls. Since αSMA identifies both blood vessels as well as
myofibroblasts, we further employed IHC analysis to determine αSMA expression only
in vessels (Appendix F). While no significant differences were measured between the
sham-injected (0.18% ±0.033) and the VEGF-treated mice (0.23% ±0.066), we did
measure a significant increase in αSMA-positive vessels in hind limb muscles treated
with both VEGF and ANG1 (0.36% ±0.054) relative to either sham or VEGF-treated
mice (p<0.0001). Many newly formed αSMA-positive vessels were detected at the
injection area in VEGF+ANG1-treated hind limbs. Very few mature vessels were
observed at the injection site of VEGF-treated hind limbs.
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A%

B%

Sham%

VEGF%

VEGF+ANG1%

Figure 4.2: Perfusion measured at endpoint is not significantly different between
hind limbs, regardless of treatment.
(A) Schematic representation of treatment groups. “Sham” group mice received PBSsoaked beads in both hind limbs. “VEGF” mice received PBS-soaked beads in the right
hind limb and VEGF-coated beads in the contralateral limb. VEGF+ANG1 mice received
VEGF-coated beads in the right hind limb and VEGF+ANG1-coated beads in the
contralateral limb. (B) Blood flow and blood volume did not differ between hind limbs,
allowing for perfusion measurements to be assessed based on the averaged BF and BV
following treatment. n=5 for sham, n=6 for VEGF, n=5 for VEGF+ANG1, P < 0.05, by
Wilcoxon signed-rank test.
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Table 4.1: Mean absolute values (mean ± SD) of blood flow (BF) and blood volume
(BV) for each experimental group at baseline.
P-values to the right of each mean column indicate that no significant difference existed
between treatment groups at baseline. n=5 for sham, n=6 for VEGF, n=5 for
VEGF+ANG1, P < 0.05, by one-way ANOVA.

Treatment

Absolute BF

BF

Absolute BV

BV

±SD

p-value

±SD

p-value

Sham

59.8 ± 25.1

VEGF

51.6 ± 8.3

VEGF+ANG1

36.8 ± 9.8

7.1 ± 3.1
0.1008

4.7 ± 2.2
3.8 ± 1.6

0.1007
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Figure 4.3: Low dose delivery of pro-angiogenic growth factors does not affect blood
flow 18 days post-treatment in mdx/utrn+/- hind limb skeletal muscle.
A. Representative blood flow maps of sham-injected, VEGF- and VEGF+ANG1-treated
hind limbs attained from dynamic contrast-enhanced computed tomography. Display
field of view = 5cm. B. Blood flow decreased in all but two mice over the course of the
study. Blood flow was not affected by either treatment groups compared to the sham
controls. n=5 for sham, n=6 for VEGF, n=5 for VEGF+ANG1, by one-way ANOVA.
Error bars represent SD.
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Figure 4.4: Ischemia-related reduction in blood volume is circumvented by
VEGF+ANG1 treatment in mdx/utrn+/- hind limb skeletal muscle.
A. Representative blood volume maps of sham-injected, VEGF- and VEGF+ANG1treated hind limbs attained from dynamic contrast-enhanced computed tomography.
Display field of view = 5cm. B. Blood volume decreased in all but two mice over the
course of the study. Blood volume was not significantly different in sham-injected and
VEGF-treated hind limbs. VEGF+ANG1 treatment resulted in significantly higher foldchange in blood volume compared to the VEGF and sham group. n=5 for sham, n=6 for
VEGF, n=5 for VEGF+ANG1, *P < 0.05, by one-way ANOVA. Error bars represent SD.
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Figure 4.5: VEGF+ANG1 increases vessel maturation following treatment in
mdx/utrn+/- GM muscle.
A. Western blot analysis of total alpha smooth muscle actin (αSMA) expression in GM
tissue homogenates following treatment. B. Immunohistochemical analysis of αSMApositive vessels, represented as percent image area. n=6 for all groups **P < 0.01, ***P <
0.001,

by

one-way

ANOVA.

Error

bars

represent

SD.

C.

Representative

immunofluorescence images of αSMA expression in sham-injected, VEGF- and
VEGF+ANG1-treated GM muscles. D. Growth factor-coated beads are visible at the
injection site. More αSMA-positive vessels are detected at the injection site of
VEGF+ANG1-treated hind limbs compared to VEGF-treated hind limbs. Scale bar=100
μm.
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4.4.4

VEGF and ANG1 reduce leukocyte infiltration and
inflammation in gastrocnemius muscle of mdx/utrn+/- mice

To assess the effect of VEGF alone, or in combination with ANG1, on vascular
permeability, we measured the level of CD45 expression, indicative of leukocyte
infiltration (Gordon et al. 2013). Expression was assessed via Western blot and IHC
analyses (Figure 4.6). While muscle treated with VEGF alone (0.35 ±0.03%) did not
exhibit significantly different levels of CD45 compared to the sham-injected controls
(0.29 ±0.04%), co-administration of VEGF and ANG1 did significantly reduce leukocyte
infiltration (0.15 ±0.04%, p= 0.0084). Since CD45 only identifies infiltrating leukocytes
and not resident macrophages already present in the skeletal muscle, H&E staining was
employed to qualitatively assess the general degree of inflammation following treatment.
Both the sham-injected and VEGF-treated muscles were observed to have diffuse clusters
of inflammatory cells throughout the muscle. In contrast, muscle treated with
VEGF+ANG1 exhibited little inflammation, with the majority of tissue devoid of
inflammation.

4.4.5

VEGF and ANG1 decrease collagen deposition compared to
VEGF alone in gastrocnemius muscle of mdx/utrn+/- mice

To assess the effect of VEGF alone or a combination of VEGF and ANG1 on muscle
fibrosis, we measured collagen deposition using Masson’s Trichrome stain (Figure 4.7).
There was no significant difference in collagen deposition between either the shaminjected (9.82 ± 3.1%) or VEGF-treated (12.61 ± 3.1%) hind limb muscles. In contrast,
hind limb muscle treated with the combination of VEGF and ANG1 exhibited only
7.6±2.2% collagen deposition, and this difference was determined to be significantly
lower than the amount of collagen deposition measured in VEGF-treated muscle
(p=0.0247).
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Figure 4.6: VEGF+ANG1 decreases leukocyte infiltration following treatment in
mdx/utrn+/- GM muscle.
A. Western blot analysis of CD45 expression in GM tissue homogenates following
treatment. B. Immunohistochemical analysis of CD45, represented as percent image area.
n=6 for all groups **P < 0.01 by one-way ANOVA. Error bars represent SD. C.
Representative immunofluorescence images of a-CD45 expression in sham-injected,
VEGF- and VEGF+ANG1-treated GM muscles D. H&E staining was used to
qualitatively assess the extent of inflammation following treatment. Inflammatory foci
are present in all groups, but only small, sparse clusters are present in muscle that
received the VEGF+ANG1 treatment. Scale bar=100 μm
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Sham)

VEGF)

VEGF+ANG1)

Figure 4.7: VEGF+ANG1 decreases collagen deposition following treatment in
mdx/utrn+/- GM muscle.
A. Representative Masson’s Trichrome-stained tissue sections of sham-injected, VEGFand VEGF+ANG1-treated GM muscles. Scale bar=100 μm B. Quantification of collagen
deposition (blue), represented as percent image area. n=6 for all groups *P < 0.05 by oneway ANOVA. Error bars represent SD.
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4.5 Discussion
Vascular endothelial growth factor (VEGF) and angiopoietin-1 (ANG1) are
increasingly being considered for their potential role in reducing or attenuating the
muscle ischemia observed in patients with Duchenne muscular dystrophy (DMD)
(McClung et al 2015). While prior studies suggest a potential role for these factors in
enhancing endogenous repair and cell therapy, studies remain to directly investigate the
effects of either factor on functional perfusion in a non-invasive manner. Therefore, in
the present study, we utilized the mdx/utrn+/- mouse, a murine DMD model more prone
to fibrosis than the commonly used mdx mouse, to measure functional perfusion via
dynamic contrast-enhanced computed tomography (DCE-CT). The short-term effect of
VEGF alone or in combination with ANG1 was assessed following a low dose, localized
delivery for 16 days. Given the high degree of variability between animals with respect
to baseline perfusion parameters, the ability to monitor vascular-targeted therapy over
time in the same animal is particularly valuable. DCE-CT is a safe and effective means to
monitor both disease progression and therapeutic efficacy and shows promise for scaling
preclinical studies directly to patients (Stewart et al 2006, Sahani et al 2007). Importantly,
we provide the first evidence that VEGF alone is not sufficient to affect functional
perfusion parameters in the hind limb skeletal muscle at the dose and duration
investigated. In comparison, co-administration of VEGF and ANG1 reduced muscle
ischemia over the course of the treatment period, as evidenced by a less marked reduction
in blood volume relative to control groups. This finding also highlights the importance of
investigating perfusion parameters other than blood flow alone, since the physiological
variability of this measurement can overshadow key observations. Blood flow is subject
to a number of environmental cues that vastly change flow measurements, such as
temperature, fasting, exercise, and stress. While blood volume may also be affected by
these factors, it is a more stable function that has the ability to represent changes in the
intravascular compartment, or the space that can be perfused during the flow of blood. In
addition to the functional measurements observed in this study, we further report that
VEGF+ANG1 significantly reduced muscle inflammation related to either sham-injection
or VEGF treatment alone, as well as fibrosis, relative to VEGF treatment alone.
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The findings from this study highlight the importance of considering the stage of
disease progression in assessing vascular therapy. During the first weeks of life, murine
models of DMD display classic signs of rapid degeneration and regeneration,
accompanied by a robust inflammatory response. This phase is accompanied by a
transient increase in perfusion as assessed by DCE-CT (Ahmad et al 2011). By nine-ten
weeks of age, the disease evolves to a more degenerative state and fibrosis begins to
predominate, coinciding with a progressive decrease in perfusion. Having critically
identified a window of opportunity to intervene with therapeutics, the present study
aimed to assess the ability of a combination of VEGF and ANG1 to slow or attenuate
chronic inflammation, ischemia and fibrosis in DMD mice. Our data on endogenous
expression of the two growth factors further points to differences in the vasculature at
different phases of disease progression. Although we did not measure differences in
either growth factor in the hind limb (gastrocnemius) muscle, there was a significant
reduction in both VEGF+ANG1 in the diaphragm. Since the diaphragm develops overt
fibrosis and muscle degeneration much earlier than hind limb muscles, these differences
may point to possible differences in expression of VEGF+ANG1 in the hind limb at later
time points. Overall, having well-defined margins between the different disease states
could reveal valuable information regarding the effects of VEGF+ANG1 on perfusion,
vascular permeability, and fibrosis.
Given that we did not measure any beneficial functional effects from a low dose
of VEGF under the conditions used here, it would be worth investigating whether
exogenous VEGF treatment is even necessary or if ANG1 alone may be sufficient to
affect change, particularly at earlier stages of disease pathogenesis prior to the onset of
overt fibrosis. Since both growth factors were decreased in the more severely affected
diaphragm muscle, exogenous administration of these factors at a later disease stage may
have an even greater impact on ischemia than what we observed here. In addition to its
role in promoting vascular maturity, previous work by others has shown that ANG1
promotes satellite cell self-renewal and inhibits apoptosis (Abou-Khalil et al 2013).
Research in other vascular-related diseases such as cardiac ischemia and sepsis have
uncovered the deleterious effect that low circulating levels of ANG1 may play in these
states (Novotny et al 2008, Lee et al 2011). In human microvascular endothelial cells
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(HMVECs), serum from sepsis patients induced intercellular gap formation, and this
effect was reversed by supplementation with ANG1 (Parikh et al 2006).
Prior studies have suggested that VEGF treatment decreases fibrosis (Deasy et al
2009; Beckman et al 2013), whereas we reported an increase in collagen deposition 18
days post-treatment compared to VEGF+ANG1 treated hind limbs. This finding is in line
with our previous work showing that VEGF induces stress fiber formation in fibroblasts
derived from the GM and diaphragm muscles of mdx/utrn+/- mice. We have also
demonstrated an increase in expression of alpha-smooth muscle actin mRNA in
diaphragm fibroblasts following VEGF treatment. Importantly, studies in other fibrotic
diseases including idiopathic pulmonary fibrosis and scleroderma have shown that VEGF
exacerbates disease pathology (Maurer et al. 2014 & Hostettler et al. 2014). Still,
previous work in the DMD field has pointed to an anti-fibrotic role of VEGF. A few
variables could account for this discrepancy. The use of the mdx/utrn+/- mouse rather
than the mdx mouse, which our group has validated as a more suitable model due to its
increased development of fibrosis, may be more responsive to VEGF than its mdx
counterpart. This hypothesis speaks to the seed and soil theory whereby the mdx/utrn+/tissue may be “primed” to respond to VEGF and develop fibrosis, relative to the mdx
mouse. Another important consideration that may account for the differences between our
findings and those of others with respect to fibrosis is the disease stage assessed in the
current study. A number of studies use either young (5 to 7 week-old) or aged (6 month
old) mdx mice (Messina et al 2007). It is therefore possible that VEGF plays a reduced
pro-fibrotic role in both the early phase of the disease when acute inflammation
predominates and in later phases of the disease when overt fibrosis has occurred in the
muscle. Lastly, the dose used in this study is much lower than some doses cited in
previous studies and may account for differential effects on collagen deposition following
treatment. Regardless, a study in rabbit skeletal muscle has also indicated that long-term
delivery of VEGF increases collagen deposition. Cumulatively, these findings suggest
that the effect of VEGF on fibrosis may significantly impede its use as a therapeutic
factor in DMD. Based on the results presented here, the pro-fibrotic effect of VEGF is
circumvented when co-administered with ANG1.
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There is a critical need to detect disease changes such as ischemia in early stages
so that therapies can be developed before damage, i.e., fibrosis, is extensive and
irreversible. Advanced non-invasive imaging technologies have immense potential to
achieve this; we have used dynamic contrast-enhanced computed tomography (DCE-CT)
and positron emission tomography (PET) to identify transient “spikes” in perfusion and
18

F-fluorodeoxyglucose (18F-FDG) uptake, respectively, in the hind limb muscles of

preclinical mouse models of DMD (Ahmad et al 2011). Intensity of these spikes
correlates with disease severity, degree of inflammation, and development of muscle
fibrosis. Importantly, these studies identified a window of opportunity to intervene with
therapeutics aimed at slowing/attenuating the inflammatory/ischemic/fibrotic process, as
demonstrated in the present study. Further use of these technologies to delineate how
vascular therapies augment either endogenous muscle repair or cell replacement therapy
represent an innovative and critical approach to the treatment of muscle degenerative
disorders.
Future directions will aim to develop methods to better control the delivery of
angiogenic factors. Although it is well accepted that cell-based delivery systems
effectively deliver high payloads, there remains concerns regarding their potential protumorigenic side effects, particularly with regards to VEGF administration (Lee et al).
Additionally, although we focused on the hind limb muscles in the current study, vascular
therapy will need to be effective in other muscles involved in disease progression,
particularly the diaphragm and cardiac muscles. Indeed, fibrosis and degeneration in
these tissues account for a majority of fatalities in DMD, and therefore any promising
treatment will need to affect these muscles as well. The fact that the combination
treatment of VEGF+ANG1 resulted in a significant effect that was detected not only
histologically but also functionally supports further investigation for the use of these
factors in long term management of DMD-related ischemia, inflammation, and fibrosis.
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5

General Discussion

5.1 Chapter Summary
The research described in this thesis includes studies that advance current knowledge of
vascular-targeted therapy for the treatment of Duchenne muscular dystrophy.
Importantly, very little has been reported on whether vascular-targeted therapy may
confer functional benefits to the muscle and how angiogenic growth factors may affect
fibrosis. This research is novel in that it investigates the effect of VEGF, alone or in
combination with ANG1, in the mdx/utrn+/- mouse, a clinically relevant murine model
that mimics the manifestation of DMD in patients. We focused our studies on the phase
of disease progression when acute and rapid inflammation transitions into fibrotic
deposition and muscle degeneration, which is around 8-10 weeks of age in the
mdx/utrn+/- mouse. Given this tightly controlled timeline, we have elucidated some key
findings that have not been previously reported (Table 5.1). An important consideration is
that findings presented in this thesis include work conducted in a murine model of
Duchenne muscular dystrophy and therefore conclusions made here may not fully
translate to human DMD patients. Additionally, there are specific limitations to each
study that are discussed in the following section. Overall, this chapter will summarize the
important conclusions drawn from each study, discuss key limitations to the research, and
propose future investigative directions that will be crucial prior to moving vascular
therapy into patients.
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Table 5.1: Summary of findings from studies described in chapters 2, 3, and 4.
DM: Diaphragm muscle; GM: gastrocnemius muscle; dko: double knockout (mdx/utrn-/); : increased; : decreased
Chapter 2

Chapter 3

Chapter 4

Comparison of three murine
models of DMD

Effect of VEGF on DMD
fibroblasts in vitro

Effect of VEGF & ANG1 in vivo

Young & aged mdx/utrn+/- mice
exhibit more GM fibrosis than mdx
mice

VEGF does not affect collagen or
Ctgf/ccn2 gene expression in DM or
GM fibroblasts

Endogenous [VEGF] and [ANG1]:
mdx/utrn+/- < wild-type

Fibrosis:
GM << diaphragm (for all 3 models)

VEGF ! αSMA gene expression
DM fibroblasts

VEGF+ANG1 "hind limb ischemia

Extent of fibrosis is not different
among hind limb muscle groups

VEGF ! fibronectin in DM and GM
fibroblasts

VEGF+ANG1, but not VEGF alone,
! vessel maturation

Disease severity:
mdx < mdx/utrn+/- << dko

VEGF ! differentiation of GM and
DM fibroblasts into myofibroblasts

VEGF+ANG1 "leukocyte
infiltration, inflammation

mdx/utrn+/- is the most suitable
model for assessing longitudinal
effects of vascular therapy

DM fibroblasts are more responsive
to pro-fibrotic cues than GM
fibroblasts

VEGF+ANG1 "fibrosis
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5.2 Conclusions by chapter
5.2.1

Chapter 2- Selection of the mdx/utrn+/- mouse for DMD
research

The aim of Chapter 2 was to determine which murine model would be best suited to our
research goals for investigating vascular-targeted therapy for DMD. Disease progression
in mdx, mdx/utrn+/-, and dko mice was compared to that of healthy wild type controls.
We demonstrate that, by as early as seven to eight weeks of age, the heterozygous
mdx/utrn+/- mouse exhibits more collagen deposition (indicative of fibrosis) than agematched mdx littermates. Another important finding from this study was that collagen
deposition in the mdx mouse was not determined to be significantly higher than that
observed in healthy hind limb muscle. Other groups have shown that mdx skeletal muscle
is fibrotic compared to healthy muscle, so the discrepancy between the literature and our
findings may lie in that fact that fibrosis was compared on a spectrum along with
mdx/utrn+/- and dko muscle tissue and the effect size in our study is larger than that
comparing only mdx and wild-type.
Since our research focuses heavily on the effects on fibrosis of angiogenic growth factors,
particularly VEGF, this study allowed us to make intelligent decisions regarding the age
and model best suited to assess these effects. As a result, we incorporated 9-10 week-old
male mdx/utrn+/- mice in all subsequent studies as these mice are in the “post’ fibrotic
phase where significant collagen deposition has occured. This is a key consideration for
all DMD research. There are a number of studies that utilize young mdx mice and
subsequently report decreases in fibrosis (Deasy et al., 2009; Beckman et al., 2013).
Using an animal that is pre-fibrotic and drawing such conclusions may lead to
misinterpretation of the results and could explain some differences in our results
compared to those found in the literature.
Although use of the mdx/utrn+/- mouse allows us to offer conclusions regarding the
effect of angiogenic growth factors on fibrosis, it is clear from the findings of our study
that the dko mouse remains, by far, the most severely affected and perhaps most accurate
model of DMD. Since mdx/utrn+/- mice, like their mdx counterparts, may live up to 1-2
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years of age in a laboratory setting, the disease severity is not considered fatal as it is in
the dko mouse. As such, future studies assessing functional efficacy of treatment should
also seek to assess effects in the dko mouse prior to scaling studies to large animals or,
especially, to patients.
Overall, the findings from this study have a profound impact in the field of DMD
research, but some limitations did exist. Disease severity in mdx, mdx/utrn+/- and dko
gastrocnemius (GM) and diaphragm muscles was compared to healthy wild type
gastrocnemius and diaphragm muscles of C57BL/6 mice. Although C57BL/6 mice are
the most commonly used inbred strain, C57BL/10 mice should have been used in this
study since the mdx mouse was generated on this background and not the Bl6
background. A few studies have investigated whether behavioural and immunological
differences exist between these two strains (Deacon et al. 2007, McClive et al. 1994,
Slingsby 1995). While the differences appear to be minor, the results from these studies
highlight the need to properly select control strains. Although we would not anticipate
this discrepancy to affect conclusions drawn from the study, for the purpose of scientific
soundness, C57BL/10s were included for wild type controls in all subsequent studies.
Although collagen deposition occurs earlier in this model compared to the mdx mouse,
whether or not the difference between the two is sufficient to affect function is not
known. We used the term “collagen deposition” synonymously with “fibrosis,” but there
may in fact be a certain degree of collagen deposition that does not exert a negative
impact on muscle function. Therefore, our finding that increased collagen deposition by
7-8 weeks of age classifies the mdx/utrn+/- mouse as “more fibrotic” is an important
assumption and should be kept in mind when referring to both models in terms of
fibrogenesis.
Our use of C57Bl6 mice as the healthy control model and use of a limited definition of
fibrosis still revealed importance differences between the mdx and mdx/utrn+/- murine
models. The limitations discussed here, if addressed, would only bolster the key findings
observed in Chapter 2. Since there is increasing focus on the importance of fibrosis in
DMD, many groups are looking for superior murine models to the mdx mouse, and the
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work in this study is the first to show that phenotypic differences in collagen deposition
arise at a young age between mdx and mdx/utrn+/- mice. One of the most important
initial steps in designing a study is selection of a suitable animal model in which to
challenge hypotheses. This study rigorously tested the murine models available to us and
allowed us to definitively decide to incorporate the mdx/utrn+/- mouse in all subsequent
studies described in this thesis. This decision thus allows us to tie a number of findings
that contrast previously reported findings to the use of a model that is not commonly
cited in the literature, opening the door for a new understanding of the effects of vascular
therapy in DMD.

5.2.2

Chapter 3- Role of VEGF in eliciting a fibrotic response

The aim of the studies described in Chapter 3 was to investigate whether exogenous
levels of VEGF may exacerbate the fibrotic response in fibroblasts derived from the
mdx/utrn+/- mouse. In other fibrotic diseases, particularly idiopathic pulmonary fibrosis,
elevated VEGF levels correlate with more rapid disease progression. Whether this
relationship is causative or correlated is not fully understood. Studies in rodents indicate
that blocking VEGF signaling can reduce fibrosis in mice and administering VEGF
exogenously can exacerbate fibrosis in rats (Hamada et al. 2005; Farkas et al. 2009).
Given these observations in other pathologies, we sought to determine whether VEGF
might play a role in increasing fibrosis in DMD fibroblasts. Although we did not observe
robust induction of a fibrotic response following VEGF treatment, as we did following
TGFβ treatment, there were multiple findings that may point to a possible role of the
growth factor in exacerbating fibrosis. Collagen and Ccn2/ctgf gene expression were
unaffected by VEGF treatment. Interestingly, we did not measure an increase in
fibronectin (Fn1) gene expression following treatment with either VEGF or TGFβ.
When we assessed protein expression, FN levels increased following VEGF but not
TGFβ treatment. This is a particularly interesting finding since TGFβ is well known to
induce FN production in fibroblasts derived from lung and other fibrotic tissues, and we
did not observe such a response here (Torr et al. 2015; Serini et al. 1998). VEGF binding
domains have been identified on FN, and it has been shown that VEGF binding to FN
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increases the biological activity of VEGF by promoting a physical interaction between
the type 2 VEGF receptor (VEGFR-2) and its integrin α5β1 receptor (Wijelath et al.
2002). Given the role of this interaction, it is plausible that VEGF treatment resulted in
increased protein levels, but not as part of a fibrotic response. VEGF expression has been
shown to increase following FN administration, but not the other way around, as we
observed in this study. This is a finding that warrants further exploration.
One of the most intriguing findings from this study is that VEGF increased gene
expression of alpha smooth muscle actin (Acta2) in diaphragm fibroblasts. Gene
expression increased to a level similar to that following TGFβ treatment. Although VEGF
led to a 1.4-fold increase in Acta2 expression in GM fibroblasts, this change was not
considered significant given the high variability in this data set. As such, it should not be
fully accepted that VEGF does not induce αSMA gene expression in fibroblasts derived
from the GM muscle. In both GM and diaphragm fibroblasts, we observed formation of
αSMA-positive stress fibers, a hallmark feature of myofibroblasts, following VEGF
treatment. Myofibroblasts are a major cellular contributor to fibrotic tissue and
differentiation of fibroblasts into this more contractile phenotype is suggestive of
induction of the fibrotic response. These findings point to a potential role of VEGF in
exacerbating fibrosis in DMD, which is a finding that contradicts previous studies
showing a decrease in fibrosis following VEGF treatment in mdx mice.
There are some areas for improvement that could be addressed in future studies. Previous
research in the past decade has highlighted the importance of an appropriate substrate for
culturing and investigating fibroblasts in vitro (Hinz et al. 2015).

Mimicking

physiological substrate stiffness relevant to the tissue of interest is key in reproducing
cellular responses that accurately reflect the in vivo scenario. Although the differences in
our findings between diaphragm and GM-derived fibroblasts indicate their fibrotic
phenotypes were maintained in culture, some changes might have resulted due to our
culturing on a collagen skim coat rather than a three-dimensional matrix. In vivo, tissues
range from very soft, such as bone marrow, to very hard, such as bone. Muscle tissue is
mid-range, but moderately stiff compared to many other tissues. The culture conditions
should attempt to mimic the stiffness of skeletal muscle ECM since others have shown
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that matrix stiffness determines the biological activity of TGFβ available to cells. Thus, if
our culture conditions were “too stiff,” there may have been an abundance of TGFβ
available to produce a basal fibrotic response in all treatment groups. This explanation
may account for the relatively low fold increase in gene expression observed in the TGFβ
treatment group. Although this is a possibility in our study, we do not believe it played a
major role in affecting our data since our immunocytochemistry results reveal little
differentiation in the untreated control fibroblasts compared to either TGFβ- or VEGFtreated cells. If our culture conditions were severely affecting TGFβ levels, we would
have expected to see a high degree of differentiation in the fibroblasts, indicated by
αSMA-positive stress fibers.
Although resident fibroblasts are the most studied cell type involved in fibrogenesis,
recent work by others has revealed a possible role for others cells in the process as well.
Pericytes, which are located around the endothelium and are surrounded by basal lamina,
have been shown to differentiate into myofibroblasts and contribute to ECM production
(Schrimpf et al. 2011). The exact role of pericytes in healthy and diseased skeletal
muscle has not been well defined, and this is in part due to the fact that different subpopulations of pericytes may have different roles in skeletal muscle repair, angiogenesis,
innervation, adipogenesis, and fibrosis (Dellavalle et al. 2007, Birbrair et al. 2013a,b,c).
Thus, without proper isolation of specific subtypes, information gleaned from pericyte
studies could under- or overestimate their role in fibrosis. For example, only a specific
subpopulation of Nestin-NG2+ pericytes has been shown to have myogenic properties
capable of regenerating muscle. Another sub-population of nestin+NG2+ pericytes,
termed type 1 pericytes, participates in fibrogenesis in aged skeletal muscle. These type 1
pericytes, when stimulated with TGFβ, produce collagen and are positive for fibroblastspecific protein 1. It should be noted, though, this fibrogenic capacity of type 1 pericytes
is more pronounced in aged mice, and it has not be fully determined whether these cells
play a role in non-age related fibrotic disease such as DMD (Birbrair et al. 2013d).
Fibro/adipogenic progenitor cells (FAPs) have also been identified recently as a cell type
contributing to fibrogenesis (Joe et al. 2010, Uezumi et al. 2010, 2011, Judson et al. 2013,
Contreras et al. 2016). Like pericytes, these cells can undergo myogenesis and repair
injured muscle or during the aging process. These integrin-α7−Sca1+PDGFR-α+ cells
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have been identified as a major source of extracellular matrix production in repair
mechanisms of healthy skeletal muscle. In normal repair processes, these FAPS
proliferate upon injury, heal the damaged muscle, and then become quickly quiescent
until once again needed. In the mdx mouse, this normal process appears to be affected
and FAP numbers do not sufficiently reduce during the repair process and therefore
contribute to the fibrogenic pool of cells (Lemos et al. 2015).
It is well accepted that myofibroblasts are the major source of fibrosis in DMD and other
diseases (Klingler et al., 2012). The knowledge gap that currently exists lies in not fully
understanding the origin of these myofibroblasts. Work by others has demonstrated a role
for pericytes and FAPs in the fibrogenic response. The study described in chapter 3
assessed the effect of vascular therapy on resident fibroblasts. Whether VEGF elicits a
fibrotic response in these other cell types is not currently known and we cannot
extrapolate our conclusions to apply to FAPS and pericytes. Thus, given the potency of
these cells in promoting fibrogenesis, future studies should address the possibility of offtarget effects of VEGF on these cell populations as well.
Though these other cell populations remain to be explored, VEGF elicited some
components of a fibrotic response in resident DMD fibroblasts, which is a novel finding
that has not been previously reported. Additionally, we show that fibroblasts derived
from environments that differ in disease severity (i.e. diaphragm and GM muscles), are
phenotypically distinct and respond differently to pro-fibrotic cues. Taken together, these
results reveal unexplored territory for future work and could drastically alter our
understanding of the interplay between fibrosis and angiogenesis in DMD.

5.2.3

Chapter 4- Effect of VEGF and ANG1 on Functional
Perfusion

The aim of chapter 4 was to determine what effect, if any, pro-angiogenic factors exert on
functional perfusion in vivo in the mdx/utrn+/- mouse. Specifically, we sought to
determine whether VEGF alone, when delivered locally, was sufficient to affect
functional perfusion or if another factor is required. In this study, we tested VEGF alone
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or in combination with angiopoietin-1 (ANG1). Dynamic contrast-enhanced computed
tomography (DCE-CT) was employed to assess the efficacy of vascular-targeted therapy
in dystrophic murine skeletal muscle in affecting blood flow and blood volume. DCE-CT
is a novel way to examine muscle perfusion because it can assess global blood flow
throughout the hind limb, a benefit not afforded by other modalities such as laser Doppler
imaging. Although perfusion decreased over the duration of the study, consistent with
progression of ischemia, the degree to which blood volume decreased was less marked in
mice that received VEGF+ANG1 in combination. We did not measure a significant effect
using VEGF alone when compared to the sham-injected group. Assessment of vessel
maturation, indicated by αSMA-positive vessels, validated the imaging findings.

In

addition to vessel maturation, the combination VEGF+ANG1 treatment resulted in
reduced collagen deposition and leukocyte infiltration compared to either the sham or
VEGF group, suggesting a potential anti-fibrotic and anti-inflammatory role of
VEGF+ANG1 in DMD.
Because the previous study, described in chapter 3, suggested VEGF may enhance the
fibrotic response in DMD, we investigated the effect of VEGF with and without ANG1
on fibrosis in vivo. Our statistical analysis determined that collagen deposition was not
significantly different between sham-injected and VEGF-treated hind limbs, but the 3%
difference in collagen deposition should not be overlooked, as this may be sufficient to
have a biological effect in muscle function. Lastly, the only measure of fibrosis we
assessed in this study was collagen deposition via Masson’s Trichrome stain. Even
though VEGF did not exacerbate collagen deposition compared to the sham control,
further analysis of other fibrotic markers such as FN and CCN2/CTGF could reveal
different findings.
Since we showed that vessel maturation was increased following VEGF+ANG1
treatment and leukocyte infiltration was decreased, we concluded this reduction in
inflammatory cells at the site of muscle injury could play a role in reducing fibrosis.
Since inflammatory cells are the major source of TGFβ (which then acts on fibroblasts to
induce extracellular matrix production) reducing the number of these cells in muscle
tissue may be an effective way to reduce chronic inflammation that lays the foundation
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for the eventual fibrosis. Although we quantitatively assessed infiltration of CD45positive leukocytes, we only performed a qualitative analysis of total inflammation using
the hematoxylin and eosin stain. Infiltrating leukocytes are not the only cellular player
involved in skeletal muscle inflammation, so analysis of resident macrophages may
reveal an even further role of ANG1 in reducing inflammation.
The delivery system used to administer growth factor treatment to mdx/utrn+/- hind limb
muscle in chapter 4 represents one of the most important limitations to this study.
Alginate beads were coated with VEGF or a combination of VEGF and ANG1. Beads
prepared for sham injection were soaked in PBS. Although we performed proof-ofprinciple studies to confirm presence of growth factor up to a minimum of 14 days postimplant (Appendix C), we were unable to calibrate the actual dose of growth factor
delivered. Insulin syringes were used for injections and some beads always remained in
the hub of the needle following implant. Further, we did not determine the variability in
coating efficiency for either growth factor. Given these considerations, we cannot
ascertain that a consistent dose of either VEGF or ANG1 was administered each time.
Further, although the alginate beads are relatively small, ranging in size from 50 to
100um, the bolus of beads (approximately 100 per injection) remained at the injection
site for as little as 4 weeks post-implant. Given this observation, the beads themselves
may have induced a minor chronic inflammatory response, which may have contributed
to overall disease progression. Although we attempted to deliver just a localized dose, our
analyses reveal that the GFs likely exerted systemic effects, as evidenced by a lack of
difference in perfusion between control and treated contralateral hind limbs. Localized
drug delivery can often be beneficial, particularly in cases where potent or toxic drugs are
administered, but systemic delivery may be the ideal outcome here given the systemic
effects of disease progression. Overall, the limitations involved with this bead delivery
system highlight the need to deliver a targeted dose of growth factor, ideally
systemically, to account for these sources of variability in this study.
Use of DCE-CT has drastically improved patient care for other ischemic diseases such as
stroke (d’Esterre et al. 2012). Whether it is the optimal non-invasive imaging modality
for assessing vascular targeted therapy deserves further consideration. The reduction in
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perfusion observed in this study correlates to the time when fibrosis begins to contribute
to a significant portion of the skeletal muscle. Thus, an assumption made here is the
ischemia observed functionally is, at least in part, due to the progression of fibrosis. Since
fibrotic and non-fibrotic muscle tissue does not differ sufficiently in density, these tissues
cannot be well delineated on an anatomical CT scan. It would therefore be valuable to use
another imaging modality capable of measuring fibrotic tissue to validate this decline in
perfusion and corresponding increase in fibrosis. Since MRI can distinguish tissues
composed of differing water content, fibrotic tissue appears as a lower signal area than
surrounding skeletal muscle (McIntosh et al., 1998; Chen et al. 2006). Combining MRI
perfusion with anatomical imaging of fibrotic areas could strengthen the findings we
attained from CT perfusion. Other groups have used MRI to assess vasomodulation in
humans following exercise with and without taking vasoregulating compounds.
Assessing vasodilation and blood oxygenation could be another useful tool in further
clarifying assumptions made in our study (Bulte et al. 2006; Towse et al. 2005).
While taking into account these limitations, this study described a novel way to assess the
functional effects of vascular therapy for DMD using a non-invasive, clinically relevant
approach. In addition, in contrast to other reports, we do not observe an anti-fibrotic
effect of VEGF following treatment, a finding that could be partially explained by our
unique use of the mdx/utrn+/- murine model. Building on the findings from Chapter 3,
we demonstrate potential deleterious effects of VEGF alone as a treatment for DMD and
show these effects can be avoided when combined with ANG1.

5.3 Future directions
The conclusions drawn from this thesis examining vascular therapy in the mdx/utrn+/mouse have resulted in a number of questions that remain to be answered. Some of our
unanticipated findings have generated new avenues to explore and may eventually
expedite the use of vascular therapy in DMD patients. There are also a number of
findings from our in vivo work that may be extended to other fibrotic and vascular-related
diseases.
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Given the increasing attention that fibrosis is receiving for its devastating effects in
DMD, future research that explores this aspect of the disease could reveal new insights to
this process. Our in vitro work assessing the effect of VEGF on the fibrogenic response in
resident fibroblasts pointed to altered fibrotic phenotypes based on the muscle from
which these cells were derived. Since we demonstrate that diaphragm fibroblasts are
more responsive to TGFβ and VEGF while GM fibroblasts appear to be more resistant to
these cues, we hypothesize altered signaling occurring in these different populations.
Future work in our lab will focus on performing microarray gene analysis to determine if
there is a novel gene or combination of genes that is/are up- or down-regulated in fibrotic
cells. Work in Dupuytren’s disease, a fibrotic disease of the palmar fascia, reveals
differential gene expression in fibroblasts isolated from the lesion versus fibroblasts
parallel to the lesion (Satish et al. 2008). These findings suggest that similar profile
differences could exist in diaphragm versus GM fibroblasts to reveal potentially novel
molecular targets for future treatments.
One of the most encouraging findings attained from this research was that VEGF+ANG1
treatment prevents overt ischemia, as was observed with VEGF treatment alone. Future
studies should aim to determine whether VEGF is even necessary to achieve the desired
effects from vascular therapy or if ANG1 treatment alone is sufficient. Given that VEGF
produces leaky vasculature and it is implicated in hemangioma formation when
administered at a sufficiently high dose, avoiding exogenous use of this growth factor
might be ideal in DMD (Lee et al. 2000). Use of ANG1 in other disease models such as
acute lung injury and sepsis suggest that protecting against vascular leakage is a powerful
approach for attenuating undesired downstream consequences (Huang et al. 2008; Fang et
al. 2015). Future studies in our lab should also seek to use cartilage oligomeric matrix
protein (COMP)-ANG1, a soluble ANG1 derivative that has more potent effects on the
Tie2 receptor than does ANG1 (Cho et al. 2004, 2005, Ryu et al. 2015).
Although work in other fields point to the possibility of using ANG1 alone as a treatment,
further work is required to assess whether the effect of VEGF on endogenous repair and
cell therapy is ultimately a justified use of the growth factor as a treatment. Since prior
studies have shown that VEGF enhances efficacy of cell therapy by optimizing paracrine
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effects, VEGF may still play an important therapeutic role that is independent of its effect
on perfusion (Beckman et al. 2013). Having now identified a disease time point whereby
intervention might be optimal, future studies in our lab will investigate whether vasculartargeted therapy will enhance survival of satellite cell transplants. Since it is well
accepted that transplanted cells exert their effects by way of paracrine signaling,
increasing their survival post-transplant may be an effective way of enhancing their
function. Future studies in our lab will use other non-invasive imaging modalities to
target satellite cells post-implant (Appendices G-I). Satellite cells expressing luciferase
and/or a mutant herpes simplex virus type 1 sr39 thymidine kinase can be non-invasively
targeted using bioluminescence or positron emission tomography imaging, respectively
(Ray et al., 2007. Thus, we can directly assess the effect of VEGF on cell transplant
survival in longitudinal manner that circumvents the need for repeated ex vivo analysis.
A promising new avenue for vascular therapy is development of a targeted delivery
system. Targeted drug delivery is a rapidly emerging in the field of cancer research for
delivering chemotherapy drugs and radioligands for tumour treatment and imaging,
respectively (Khaw et al., 2014). Use of a targeted drug delivery system could have a
number of benefits for vascular therapy in DMD. A targeted system would circumvent
the use of viral delivery as well as allow for systemic delivery to all damaged muscle,
especially ones that are difficult to reach via intramuscular injection such as the
diaphragm. This ability to target the diaphragm may be the most important factor since
disease progression in the respiratory muscles is the major contributing factor to DMD
mortality (Khirani et al., 2014). In all three murine models of DMD discussed in this
thesis, fibrosis and muscle degeneration in the diaphragm far exceeds that observed in the
hind limb muscles. Thus, regardless of the animal model used, any study that reports
efficacy in the diaphragm represents more potential than efficacy reported elsewhere in
the body. Systemic delivery would also allow for administration of low doses with little
off target effects, addressing the issues related to hemangioma formation following
VEGF treatment. In order to develop a targeted drug delivery system, a marker specific
to damaged muscle will need to be identified. Markers that would be up regulated in the
inflammatory response, such as CCR2 and E-selection, or markers up regulated in the
fibrotic response, such as CCN2/CTGF or ADAM12, are attractive candidates
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(Mojumder et al. 2014, Farini et al. 2007). A key consideration here is targeting a
biomarker without affecting function, if function is still desired. On the other hand,
neutralizing the activity of some of these markers with the use of an antibody might have
synergistic effects that add to the benefits of vascular therapy.
Overall, the research described in this thesis links two-dimensional histological effects of
vascular therapy to non-invasive, global changes following treatment. Future work should
answer questions relating to vascular therapy that we did not investigate within the body
of this work. Three-dimensional histopathology reconstruction and intravital video
microscopy may describe parameters of angiogenic therapy not answered by DCE-CT.
Such parameters include vessel enlargement, tortuosity, blood oxygenation, and degree of
branching/bifurcation following treatment (Xu et al., 2015; Frontini et al., 2011; Novielli
& Jackson, 2014). Combining our findings with these techniques may have profound
impacts on the way we utilize vascular-targeted therapy in the context of DMD.
Despite tremendous advances in care for patients living with DMD, the disease remains
invariably fatal. Vascular-targeted therapy is just one therapeutic approach currently
under investigation. While the findings described in this thesis support the use of proangiogenic growth factors for DMD, it is the prevalent opinion in the field that any
eventual cure will involve a multifaceted approach. Thus, our long-term goal is to work
in concert with groups investigating ways to reintroduce dystrophin to DMD patients, a
combinatorial approach that may truly extend life expectancy and, importantly, improve
quality of life.
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Appendix A: Colour thresholding to analyze collagen content in histological sections
stained with Masson’s Trichrome.

Quantifying collagen deposition in Masson’s Trichrome stained tissue sections. 5um
sections of gastrocnemius tissue were stained with Masson’s Trichrome (A,B) on
separate days and imaged on a Zeiss Microscope using different exposure windows,
producing different hues of blue (collagen) and orange (muscle).

Images were

transformed into Lab colour space allowing the isolation of the colour and lightness
components of each pixel. A k-means clustering algorithm was then applied to the colour
components of each individual image to partition the pixels into groups of relatively ‘red’
or ‘blue’ colour values (C,D).
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Appendix B: Fibroblasts isolated from dystrophic mdx/utrn+/- mice.

Primary fibroblasts isolated from mdx/utrn+/- muscle. Fibroblasts migrate away from
tissue explants (shown above: diaphragm fibroblasts). Immunocytochemistry confirms
presence of fibroblasts by assessing vimentin and CCN2 expression. Scale bar=50μm.
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Appendix C: ELISA analysis demonstrates that localized delivery of vascular
endothelial growth factor (VEGF165) results in slow release of the growth factor for
up to two weeks post-injection.
Distance from
injection site
Very distal
Distal
Proximal
Directly at site

VEGF164 levels following intramuscular implantation of VEGF164-coated beads.
Alginate beads were coated with 0.5ug of recombinant human VEGF165 and injected into
the lateral head of the gastrocnemius muscle of mdx mice. At 3, 7, and 14 days postinjection, mice were sacrificed and tissue was collected for ELISA analysis (n=2 per time
point). Tissue was collected from four different regions to indicate how far VEGF
treatment diffused (tissue directly surrounding and including the injection site [black],
tissue less than 5mm from the injection site [dark grey], tissue more than 1cm from the
injection site [medium grey], and tissue from the contralateral limb [light grey]). VEGF
was still measured 14 days post-implant. Note: No cross-reactivity with mouse VEGF164
was detected using this assay.
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Appendix D: Results from initial perfusion study using 5-7 week-old mdx mice

Blood flow and blood volume perfusion maps acquired from DCE-CT scans at
baseline and two weeks following treatment with pro-angiogenic growth factors.
Mdx mice were injected with either PBS and VEGF-coated beads (A,C,E,G) or VEGF
and VEGF+ANG1-coated beads (B,D,F,H) . Mice were scanned at baseline (A,B,E,F)
and two weeks post-implant (C,D,G,H). Blood flow (A,B,C,D,I) and blood volume
(E,F,G,H,J) were measured using CT Perfusion 5 software (n=5, p<0.05).
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Appendix E: Dynamic contrast-enhanced CT scans acquire data that can be used to
attain functional perfusion maps.

An anatomical and functional map acquired from DCE-CT scans. An axial
anatomical scan (A) yields cross-sectional images. Bony landmarks such as the tail,
fibula and tibia are easily identified. A black void is visible after injection of Affi-Gel
Blue Gel beads (either soaked in PBS or coated with growth factor). Following a bolus of
iodinated contrast agent, a series of one-second scans are taken to acquire functional data.
CT Perfusion 5 software is used to generate perfusion maps (B).
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Appendix F: Quantifying fluorescence images to include αSMA+ blood vessels and
exclude αSMA+ myofibroblasts

Green arrows
identify vessels
Pink brackets
identify
myofibroblasts

Raw immunofluorescence image

An

anti-αSMA

primary

antibody

marks

both

Segmented image

mature

vasculature

and

myofibroblasts in dystrophic muscle. To accurately quantify mature blood vessels
(green arrows) on histological sections, extreme care must be taken to exclude αSMA+
myofibroblasts (pink brackets). Implementation of a semi-automatic grey scale
thresholding algorithm detects presence of vessels only (pink signal in segmented image).
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Appendix G: Molecular Imaging to Target Transplanted Muscle Progenitor Cells4
Introduction
Duchenne muscular dystrophy (DMD) is a severe genetic neuromuscular disorder that
affects 1 in 3,500 boys, and is characterized by progressive muscle degeneration (Emery
2002; Blake et al. 2002). In patients, the ability of resident muscle satellite cells (SCs) to
regenerate

damaged

myofibers

becomes

increasingly

inefficient4.

Therefore,

transplantation of muscle progenitor cells (MPCs)/myoblasts from healthy subjects is a
promising therapeutic approach to DMD. A major limitation to the use of stem cell
therapy, however, is a lack of reliable imaging technologies for long-term monitoring of
implanted cells, and for evaluating its effectiveness. Here, we describe a non-invasive,
real-time approach to evaluate the success of myoblast transplantation. This method takes
advantage of a unified fusion reporter gene composed of genes (firefly luciferase [fluc],
monomeric red fluorescent protein [mrfp] and sr39 thymidine kinase [sr39tk]) whose
expression can be imaged with different imaging modalities (Ray et al. 2004, 2007). A
variety of imaging modalities, including positron emission tomography (PET), singlephoton emission computed tomography (SPECT), magnetic resonance imaging (MRI),
optical imaging, and high frequency 3D-ultrasound are now available, each with unique
advantages and limitations (Massoud & Gambhir 2003). Bioluminescence imaging (BLI)
studies, for example, have the advantage of being relatively low cost and highthroughput. It is for this reason that, in this study, we make use of the firefly luciferase
(fluc) reporter gene sequence contained within the fusion gene and bioluminescence
imaging (BLI) for the short-term localization of viable C2C12 myoblasts following
implantation into a mouse model of DMD (Sicinski 1989; Mattson 2001; Anderson et al.

4

This appendix includes content reproduced with permission from

Gutpell K, McGirr R, Hoffman L (2013). Molecular Imaging to Target Transplanted Muscle Progenitor
Cells. J Vis Exp (73), e50119, doi:10.3791/50119.
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1988). Importantly, BLI provides us with a means to examine the kinetics of labeled
MPCs post-implantation, and will be useful to track cells repeatedly over time and
following migration. Our reporter gene approach further allows us to merge multiple
imaging modalities in a single living subject; given the tomographic nature, fine spatial
resolution and ability to scale up to larger animals and humans (Massoud & Gambhir
2003), PET will form the basis of future work that we suggest may facilitate rapid
translation of methods developed in cells to preclinical models and to clinical
applications.
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Protocol
Maintenance and Propagation of C2C12 Myoblasts
1. Plate C2C12 myoblasts in a 75 cm2 flask and maintain cells in high glucose
Dulbecco's Modified Eagle's Serum (HG-DMEM) supplemented with fetal bovine
serum (FBS) to a final concentration of 10%. Do not allow cells to become confluent
at any time, as this will deplete the myoblast population. Medium should be changed
every other day. Note: always warm medium to 37 °C in a water bath prior to use.
2. When myoblasts become approximately 80% confluent, passage cells to a new flask.
Aspirate culture medium. Wash cells with 4-5 ml Hanks Balanced Salt Solution
(HBSS) to remove all traces of culture medium, which contains trypsin-inhibiting
serum. Briefly rinse the cell layer with 2-3 ml 0.25% (w/v) trypsin-EDTA solution to
dissociate the adherent myoblasts from the flask. Aspirate trypsin and place flask in
incubator at 37 °C for 5 min.
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3. During this incubation, prepare a new flask with 9 ml of HG-DMEM/10% FBS
medium. After trypsinization, add 10 ml of complete medium to cells and pipette 4-5
times to ensure collection of all cells in the medium. Add 1 ml of cell suspension to
the new flask and incubate in 5% CO2 at 37 °C.
C2C12 Cell Transfection
1. Once cells have reached 50% confluency, transfect according to manufacturer's
instructions from Invitrogen. Briefly, combine 90 μl Lipofectamine 2000 reagent with
4.5 ml OPTI-MEM medium. In another tube, combine 36 μg CMV-trifusion reporter
gene DNA with 4.5 ml OPTI-MEM. Flick each tube to combine and wait 5 min.
Combine contents of both tubes, mix gently and incubate at room temperature for
exactly thirty minutes. Note: A second flask should also be set up for untransfected
cells that only receive Lipofectamine and OPTI-MEM to serve as a negative control.
2. Remove medium from C2C12 cells and add 15.5 ml of fresh HG-DMEM/10%FBS
medium. Add transfection medium to bring total volume to 20 ml.
3. Allow cells to transfect overnight for at least 20 hr at 37 °C.
4. Next day, aspirate transfection medium and add 10 ml HG-DMEM/10%FBS.
5. View cells under an inverted fluorescent microscope. Capture both bright field and red
fluorescence images (using a TRITC filter cube; mrfp ex/em: 584/607 nm). Count the
number of RFP-expressing cells viewed under fluorescence divided by total number of
cells viewed under bright field for multiple fields of view to generate transfection
efficiency.
Assessment of Cell Survivability/MTT Assay
1. One day prior to transfection, plate 1x105 C2C12 cells into each well in a 24-well
plate. Cells should be plated in 500 μl volumes in HG-DMEM/10%FBS .
2. Next day, transfect

myoblasts overnight as previously described. Follow

manufacturer's suggestions for transfection reagent volumes for a 24-well plate.
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Incubate a set of wells with Lipofectamine only (no DNA) as a control. View cells
under fluorescence to ensure that proper transfection has occurred.
3. Remove transfection medium and incubate myoblasts with 5 mg/ml thiazolyl blue
tetrazolium bromide (MTT) in HG-DMEM/10% FBS. Add D-luciferin to eight of the
transfected wells, and incubate at 37 °C for four hours.
4. Remove medium from wells. Solubilize blue formazan crystals by adding 180 μl
isopropanol to each well. Shake at 37 °C for 15 min.
5. Avoiding any precipitate, pipette solution into a 96-well plate and read absorbance at
575 nm.
Preparation of Myoblasts for Transplant
1. Remove medium, wash myoblasts with HBSS, and trypsinize cells as outlined in 1.1.
2. Re-suspend cells in 4 ml of complete medium.
3. Using a hemocytometer, count cells to generate volumes containing 106 myoblasts.
Pipette volume into sterile 1.5 ml microtubes. With a transfection efficiency of ~10%,
these values indicate that 100,000 luciferase-expressing cells are detectable on the GE
ExploreOptix scanner after transplant.
4. Attain a final injection volume of 15 μl, containing 106 C2C12 cells. If necessary,
centrifuge microtubes at 2,000 rpm for one minute. Carefully aspirate supernatant with
a pipette. Re-suspend cells in 15 μl of HG-DMEM lacking FBS.
Cell Implantation
1. Anesthetize mouse with 2% isoflurane/2%O2. Pluck hair from the dorsal hind limb
area. Maintain anesthesia at 1.5%isoflurane/2%O2.
2. Ensure C2C12 myoblasts are well suspended. With the mouse in a prone position,
extend the hind limb and use an insulin syringe to inject cells directly into the lateral
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head of the gastrocnemius muscle at a 30 ° angle. Inject transfected myoblasts into the
right hind limb and untransfected myoblasts into the contralateral (left) hind limb.
3. Perform a baseline bioluminescence scan: Quickly transfer mouse to stage in the
optical scanner, laying the mouse in a prone position. Hook up the anesthetic line. To
ensure the mouse remains anesthetized, a second person should be present to hook up
the anesthetic line while the other places the animal in the scanner.
4. Gently extend the hind limb so the area of injection is visible. Tape hind limbs in place
with a gentle adhesive such as medical tape.
5. Close the chamber and ensure that no light can access the interior of the scanner, as
this will increase the background signal detected. The scanner should be set to
parameters included in your manufacturer's instructions for bioluminescence imaging.
Specifically, ensure "no laser" is selected.
6. Draw a region of interest (ROI) around the plucked area and start scan.
Injection of Fluc Substrate, D-luciferin, into Mdx Mouse
1. While the mouse is anesthetised intraperitoneally inject 150 mg/kg of firefly luciferase
substrate, D-luciferin (from a 40 mg/ml stock solution, made up according to
manufacturer's instructions).
2. Recover mouse and allow a 15 min uptake period before preparing mouse for the next
scan.
BLI to Target Luc-expressing MPCs Following Implant into Mouse Models of DMD
1. After the uptake period, anesthetise mouse again, as described in 5.1.
2. Transfer the mouse back to the optical scanner and perform another bioluminescence
scan in the same manner as the background scan.
3. Although a 20 min uptake period should provide maximal signal intensity, a
subsequent scan may be performed.
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4. Upon completion of image acquisition, sacrifice the mouse according to guidelines set
by your Institutional Animal Ethics Committee and the Canadian Council on Animal
Care (CCAC). Isolate hind limb muscle and place immediately in 10% formalin to fix
for paraffin embedment. Perform immunohistochemistry staining for luciferase to
confirm intramuscular injection of myoblasts.
Representative Results
Upon 50-60% confluency, C2C12 myoblasts were transiently transfected with the abovementioned fusion reporter gene construct composed of firefly luciferase [fluc],
monomeric red fluorescent protein [mrfp] and sr39 thymidine kinase [sr39tk](Figure 1A).
Transfection efficiency was calculated via fluorescence microscopy (Figures 1B,C),
making use of the mrfp sequence in our reporter construct. Cell survivability was not
affected by labeling with the BLI substrate, D-luciferin (Figure 1D). Following
transfection, approximately 100,000 mrfp-expressing myoblasts were implanted
intramuscularly into the gastrocnemius muscle of mdx mice (determined previously);
100,000 untransfected cells were similarly implanted into the contralateral hind limb as a
control. Immediately following cell implantation, mice were injected intraperitoneally
(IP) with 150 mg/kg D-luciferin. Following an uptake period of ~20 min, mice were
imaged on a small animal optical scanner (GE ExplorOptix black box that is equipped for
live animal bioluminescence and fluorescence). As previously demonstrated, both in vitro
and post-implantation (manuscript submitted) uptake of D-luciferin were specific to flucexpressing myoblasts, with no detectable bioluminescence in untransfected cells (Figure
2). Immunohistochemistry confirmed intramuscular transplantation of myoblasts.
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Figure 1. Schematic of CMV-trifusion reporter construct (A); brightfield/fluorescence
images of C2C12 myoblasts transfected with the trifusion reporter plasmid (B,C); MTT
assay to assess C2C12 cell survivability following labeling with BLI substrate, Dluciferin (D).
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A

B

Figure A2. Bioluminescence imaging (BLI). BLI targets luciferase-expressing cells
following transplant (A). A region of interest is drawn to enclose the plucked hind limb
area where myoblasts are injected. Bioluminescence is not detected during a background
scan. At 23 min after injection of D-luciferin, a clear signal is detected from the right
hind limb where luciferase-expressing myoblasts are injected. No bioluminescence is
detected in the contralateral hind limb injected with untransfected myoblasts. IHC using a
firefly luciferase antibody confirms intramuscular implantation of transfected C2C12
cells (B). DAPI was used as a counterstain. Scale bar= 50um.
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Discussion
In this study, we have described a fast and reliable molecular imaging, reporter gene
approach to non-invasively target myoblasts/MPCs following transplantation. While this
study demonstrates the short-term localization of transplanted MPCs via bioluminescence
imaging (BLI), the manner in which cells are targeted can, in fact, be easily applied to a
longitudinal assessment of cell engraftment, through the implantation of cells that stably
express the reporter gene. To this end, our group has generated transgenic mouse lines
that harbour the unified reporter gene. Only cells expressing the reporter gene oxidize Dluciferin to produce photons for visualization using BLI. Since oxidation of D-luciferin is
dependent on gene expression, this is a powerful technology with which to noninvasively image viable transplanted cells. Muscle tissue harvested from these transgenic
mice and satellite cells (SCs) isolated via FACS can indeed be targeted following
implantation into mdx mice. Additionally, we can track their differentiation status
through the use of a muscle-specific promoter, further heightening the usefulness and
importance of molecular imaging technologies, such as presented herein, to the field of
DMD research. In addition to its rapidity and low-cost, BLI is non-toxic, making it an
attractive choice for frequent imaging of small animals. This feature, as well as its high
specificity, will be invaluable in refining myoblast replacement therapies in pre-clinical
disease models of Duchenne muscular dystrophy before advancing to clinically
applicable studies involving technologies such as PET.
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Appendix H: C2C12 myoblasts expressing the trifusion reporter under control of
the myogenin promoter can be targeted ex vivo following injection

Immunohistochemistry confirms intramuscular implantation of myogenin-FMTexpressing C2C12 myoblasts. Differentiated C2C12 myoblasts transiently transfected
with myogenin-FMT DNA express mRFP (A). Bright field and fluorescence images
reveal an expression level of less than 1% (A, B) scale bar=50µm. One million C2C12
cells (10,000 luciferase-expressing) are transplanted into the hind limb muscle of an mdx
mouse. Immunohistochemistry confirms intramuscular implant (C-E).
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Appendix I: Fluorescence activated cell sorting of satellite cells from transgenic
mice expressing a trifusion imaging reporter driven by the muscle-specific promoter
myogenin

Satellite cells FACS-isolated from a transgenic myogenin-FMT mouse. Satellite cells
are sorted based on positive staining of alpha-7 integrin, negative staining of the lineage
markers CD31, CD45, CD11b and Ly6A/E, and a forward-scatter high profile (A). After
7 days in culture, satellite cells differentiate into myogenin-expressing myocytes that
express the mRFP reporter (B,C). Immunocytochemistry confirms differentiation along
the myogenic pathway, as indicated by the expression of MyoD and myogenin. MyoD, an
early indicator of myoblast activation, is not expressed in more differentiated cells where
myogenin is expressed (scale bar=50µm).
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Appendix K: Animal Use Protocol Approval
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